WO2016149404A1 - Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making - Google Patents

Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making Download PDF

Info

Publication number
WO2016149404A1
WO2016149404A1 PCT/US2016/022693 US2016022693W WO2016149404A1 WO 2016149404 A1 WO2016149404 A1 WO 2016149404A1 US 2016022693 W US2016022693 W US 2016022693W WO 2016149404 A1 WO2016149404 A1 WO 2016149404A1
Authority
WO
WIPO (PCT)
Prior art keywords
capture agent
ligand
protein
linker
botulinum neurotoxin
Prior art date
Application number
PCT/US2016/022693
Other languages
French (fr)
Inventor
Blake FARROW
James R. Heath
Heather Dawn Agnew
Original Assignee
California Institute Of Technology
Indi Molecular, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55642896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2016149404(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by California Institute Of Technology, Indi Molecular, Inc. filed Critical California Institute Of Technology
Priority to CN201680016366.5A priority Critical patent/CN107624115B/en
Priority to EP16713229.9A priority patent/EP3270951B1/en
Publication of WO2016149404A1 publication Critical patent/WO2016149404A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • BoNT serotype A is the most lethal known toxin.
  • BoNT is produced by some species of the bacterial genus Clostridium and is a chemodenervating zinc-dependent protease that prevents the Ca 2+ -triggered release of acetylcholine in neuromuscular junctions by cleaving one of the three SNARE proteins required for synaptic vesicle formation and release.
  • BoNT/A intoxication proceeds with selective binding to neuronal receptors, cell entry through receptor-mediated endocytosis, endosome escape via pH-induced translocation, and finally, cleavage of its SNAP-25 substrate in the cytosol.
  • BoNT/A is comprised of a receptor-binding heavy chain and disulf ide-linked catalytic light chain (LC). This disulfide bond must be intact for the toxin to poison neurons, but must be broken for the LC to act catalytically in the cytosol.
  • a subdomain (the 'belt') structurally occludes the intact holotoxin active site so that drug-induced inhibition only occurs after belt release, which is promoted by the reduction of the disulfide link by the cytosolic environment.
  • the rapid sequestration of BoNT toxins into motor neurons limits current antibody based therapies, while molecular inhibitors cannot access the occluded active site of circulating BoNT.
  • BoNT is a potentially deadly bioweapon, but is also a therapeutic and cosmetic agent, with an accompanying risk of accidental overdosing. Potent and effective inhibitors are needed.
  • the present disclosure relates to chemically synthesized capture agents (called protein-catalyzed capture agents, or PCC Agents) that are designed to bind botulinum neurotoxin (BoNT) serotype A, methods for making said capture agents, methods for using said capture agents to inhibit BoNT serotype A and treat or prevent botulism or botulin toxin poisoning.
  • PCC Agents chemically synthesized capture agents
  • a stable, synthetic capture agent that specifically binds to BoNT serotype A, wherein the botulinum neurotoxin serotype A protein comprises a heavy chain and a light chain, wherein the light chain comprises an enzymatic active site, wherein the capture agent comprises an anchor ligand and a secondary ligand and wherein the ligands selectively bind BoNT serotype A.
  • composition comprising one or more synthetic capture agents of the invention that specifically binds BoNT serotype A.
  • BoNT serotype A in another aspect, comprising the step of treating the biological sample with one or more capture agents of the invention.
  • SNAP-25 cleavage mediated by botulinum neurotoxin serotype A protein in one or more neurons in a subject in need thereof comprising administering to the neurons an effective amount of one or more capture agents of the invention.
  • method treating botulism in a subject in need thereof comprising administering a therapeutically effective amount of one or more capture agents of the invention.
  • the anchor ligand specifically binds to the enzymatic active site of BoNT serotype A.
  • the anchor ligand comprises a cyclic peptide of the formula of Dab(DNP)-R-Lys(N3)-T-Dab-Pra- L-NH-, wherein the N3 and Pra moieties together represent a Tz4 or a Tz5 linkage.
  • the anchor ligand comprises a molecule of formula lnh-1
  • R 1 is absent or is a linker to the secondary ligand.
  • the secondary ligand specifically binds to a site on the botulinum neurotoxin serotype A protein that is 3-10 angstroms away from the enzymatic active site of the botulinum neurotoxin serotype A protein. In another embodiment, the secondary ligand specifically binds the botulinum neurotoxin serotype A light chain. In another embodiment, the secondary ligand specifically binds an occluded conformation of the botulinum neurotoxin serotype A holotoxin. In another embodiment, the secondary ligand specifically binds residues 166-179 of the botulinum neurotoxin serotype A light chain.
  • the secondary ligand comprises a cyclic peptide of the formula of -Pra-NYRWL-Lys(N3), wherein the N3 and Pra moieties together represent a Tz4 or a Tz5 linkage.
  • the secondary ligand comprises a molecule of formula L2
  • R 2 is absent or is a linker to the anchor ligand.
  • the secondary ligand is selected from an epitope made up of residues 1 66-1 79 of the BoNT light chain screened against a 1 .1 million element library of macrocyclic 5-mer peptides.
  • the library is anti-screened against a scrambled version of the same epitope.
  • the capture agents described herein comprise a linker.
  • the linker is a tripeptide.
  • the linker can comprise the amino acid sequence of Gly-Aib-Leu or Leu-Aib-Gly.
  • the linker comprises PEG 4 .
  • the anchor ligand and/or the secondary ligand are linked to the linker via a 1 ,4-substituted-1 ,2,3-triazole residue (Tz4) or via a 1 ,5-substituted-1 ,2,3-triazole residue (Tz5).
  • the anchor ligand is linked to the linker via a Tz4.
  • the linker is 3-1 0 angstroms in length. In other embodiments, the linker is 5-8 angstroms in length. In other embodiments, the linker has a length between 1 00 and 1 1 0% percent of the distance between the anchor ligand and the secondary ligand.
  • the anchor ligand and secondary ligand are linked together via a 1 ,4-substituted-1 ,2,3-triazole residue (Tz4).
  • the secondary ligand and the tertiary ligand are linked together via a 1 ,4-substituted-1 ,2,3-triazole residue (Tz4).
  • the tertiary ligand and the quarternary ligand are linked together via a 1 ,4-substituted-1 ,2,3-triazole residue (Tz4).
  • the anchor ligand and secondary ligand are linked together via a 1 ,4-substituted- 1 ,2,3-triazole residue, and the secondary ligand and the tertiary ligand are linked together via a 1 ,4-substituted-1 ,2,3-triazole residue.
  • the anchor ligand and secondary ligand are linked together via a 1 ,4-substituted-1 ,2,3-triazole residue
  • the secondary ligand and the tertiary ligand are linked together via a 1 ,4-substituted-1 ,2,3-triazole residue
  • the tertiary ligand and the quaternary ligand are linked together via a 1 ,4- substituted-1 ,2,3-triazole residue.
  • a capture agent of the invention is a biligand, comprising an anchor ligand and a secondary ligand.
  • a secondary ligand Non-limiting examples of secondary ligands are also disclosed in Figure 16.
  • the capture agent comprises a molecule of formula
  • R 3 is hydrogen, a capping group (e.g., an amide), or comprises a label or a spontaneously translocating peptide.
  • the BoNT serotype A capture agents provided herein are stable across a wide range of temperatures, pH's, storage times, storage conditions, and reaction conditions, and in certain embodiments the capture agents are more stable than a comparable antibody or biologic.
  • the capture agents are stable in storage as a lyophilized powder.
  • the capture agents are stable in storage at a temperature of about -80 Q C to about 60 Q C.
  • the capture agents are stable at room temperature.
  • the capture agents are stable in human serum for at least 24 hours.
  • the capture agents are stable at a pH in the range of about 3 to about 1 2.
  • the capture agents are stable as a powder for two months at a temperature of about 60 Q C.
  • the capture agent is labeled with a label selected from the group consisting of biotin, copper-DOTA, biotin-PEG3,
  • the capture agent is labeled with the detectable moiety consisting of 64 Cu DOTA, 68 Ga DOTA, 18 F, 64 Cu, 68 Ga, 89 Zr, 124 l, 86 Y, 94m Tc, 1 10m ln, 1 1 C and 76 Br.
  • the label is a fluorescent label.
  • the detectable label is 18 F.
  • the capture agent comprises a translocating peptide.
  • These translocating peptides allow the capture agents to enter eukaryotic cells.
  • these eukaryotic cells are mammalian cells.
  • these mammalian cells are human cells.
  • the translocating peptide is a spontaneously translocating peptide.
  • the spontaneously translocating peptide comprises the amino acid sequence of pliylrllrGqf.
  • translocating peptides that can be used include H IV-TAT, penetratin, SynB1 , SynB2, PTD-4, PTD-5, FHV Coar (35-49), BMV Gag (7-25), HTLV- I I Rex (4-1 6), D-Tat, R9-Tat, transportan, MAP, SBP, FBP, MPG, Pep-1 , Pep-2, polyarginines, or polylysines. Any sequence at least 90% identical to any of the translocating peptides or fragments thereof may be used.
  • a method of inhibiting SNAP-25 cleavage mediated by botulinum neurotoxin serotype A protein in one or more neurons in a subject in need thereof comprising administering to the neurons an effective amount of the capture agent as provided herein.
  • inhibition of BoNT serotype A activity results in treatment or prevention of botulinism or botulin toxin poisoning.
  • the method comprises the steps of:
  • the method further comprises the step of:
  • step (d) e. synthesizing the capture agent comprising the anchor ligand and secondary ligand of step (a) and the linker of step (d).
  • the linking of the anchor ligand and the secondary ligand is performed using a linker.
  • the linker has a length that is between 1 00 and 1 1 0% percent of the distance between the anchor ligand and the secondary ligand when both ligands are bound to the botulinum neurotoxin serotype A protein.
  • Also provided herein are methods for making (i.e. , synthesizing) the BoNT serotype A capture agents of the invention. In one embodiment, the method comprises the steps of:
  • the secondary ligand must bind to an epitope so that it specifically binds to an occluded conformation of the botulinum neurotoxin serotype A holotoxin, thereby synthesizing the capture agent for inhibiting SNAP-25 cleavage mediated by botulinum neurotoxin serotype A protein in one or more neurons.
  • Figure 1 The development of a biligand inhibitor of BoNT/A.
  • lnh-1 (orange, Dab(DNP)-R-Lys(N3)-T-Dab-Pra-L-R1 ) is based on the natural peptide substrate for BoNT LC and previous structural studies of peptidomimetic substrate mimics.
  • Epitope targeting was used to screen for a secondary ligand targeted to a nearby unstructured epitope (BoNT LC 166-1 79, green) exposed in the presence of the holotoxin's occluding belt (red).
  • the ligand selected (L2, red, R2-Pra-NYRWL- Lys(N3)) was selected from a 1 100000 member macrocyclic peptide library.
  • Figure 2 Linker screen for divalent ligand development, lnh-1 was synthesized with a C-terminal azide and a biotin tag for readout of the in situ click screen and used in solution whereas L2 was synthesized with an N-terminal alkyne and a comprehensive linker library of oligopeptides of one to five units on Tentagel resin.
  • An in situ protein-catalyzed click screen was performed to select for a minimally perturbative correctly oriented linker and resulted in hit sequences Gly- Aib- Leu and Leu-Aib-Gly.
  • a PEG 4 linker was also used in preliminary assays as a comparison (See Figures 18 and 1 9).
  • lnh-2 was the biligand chosen for all future assays.
  • Figures 3A-3D Characterization of ligand binding and inhibition in vitro.
  • Figure 3A Inhibition curve (left axis) and fluorescence polarization binding curve (right axis) of lnh-1 .
  • An IC50 value of inhibition of 70 ⁇ 10 nM and a kp value of 68 ⁇ 29 nM were obtained by Hill curve fitting.
  • Figure 3B Inhibition curve (left axis) and fluorescence polarization binding curve (right axis) of compound L2. No inhibition was observed, and a kp value of 78 ⁇ 8 nM was determined.
  • Figure 3C Inhibition curves comparing lnh-1 (pink) to lnh-2 (red).
  • Figures 4A and 4B Ligand inhibition effect in a hiPSC-derived neuron system with BoNT holotoxin.
  • Figure 4A Top shows western blots of neuron lysates for B-tubulin (control) and SNAP (cleaved and uncleaved). The cleaved SNAP product appears as a longer running band below the intact SNAP in the western blot.
  • Assays were performed with various concentrations of compounds Inh- 1 and lnh-2 along with a known endocytosis-inhibiting polyclonal sheep anti-BoNT heavy-chain antibody. The plot below shows the percentage of intact SNAP as a function of ligand concentration.
  • Figures 5A-5C Rescuing hiPSC- derived neurons from BoNT intoxication.
  • Figure 5A Experimental timeline of 55 U bolus toxin exposure (i) and 24 our incubation with 2 U toxin (ii). The protection effect was evaluated by preincubation of the toxin with 1 ⁇ inhibiting anti-BoNT pAb or lnh-2-STP, and the rescue effect was evaluated 1 , 3, and 12 hours after exposure to toxin by lysing cells and quantitating SNAP cleavage by western blot analysis and densitometry. In all cases, the cells were lysed 24 hours after toxin exposure.
  • Figure 5B Representative western blots of neuron lysates for B-tubulin (control) and SNAP (cleaved and uncleaved) after the rescue experiments shown in Figure 5A.
  • the cleaved SNAP product appears as a longer running band below the intact SNAP in the western blot.
  • Figure 5C Percentage of intact SNAP as a function of exposure time before treatment. The percentage was calculated as the ratio of the integrated intact band intensity to the total integrated intensity of the bands. Error bars indicate standard deviation of replicates.
  • Figure 6 Click cyclized BoNT LC inhibitor (lnh-1) (Biotinylated). Sequence Dab(DNP)-R-[Lys(N3)-T-Dab-Pra]-L-PEG 4 -Biotin where square brackets indicate a closed cycle. Expected m/z 1 518.77, observed m/z 1518.61 .
  • Figure 7 Click cyclized BoNT LC inhibitor (lnh-1) (Fluorescein).
  • Figure 8 L-2 cyclic secondary binder (Biotinylated). Sequence Biotin- PEG 5 -[Pra-NYRWL-Lys(N3)] where square brackets indicate a closed cycle. Expected m/z 1516.75, observed m/z 151 6.35.
  • Figure 9 L-2 cyclic secondary binder (Fluorescein). Sequence Fluorescein-PEG 5 -Pra-NYRWL-Lys(N3) where square brackets indicate a closed cycle. Expected m/z 1648.72, observed m/z 1 648.89.
  • Figure 10 Divalent Inhibitor with in situ selected G-Aib-I linker (lnh-2).
  • Figure 11 Literature 310 helical BoNT LC inhibitor (biotinylated).
  • Figure 12 Preliminary ELISA curves of inhibitory ligands.
  • Candidate substrate mimic ligand BoNT LC binding was evaluated by sandwich ELISA and compared to the literature inhibitor (blue).
  • Figures 13A-13C Representative in vitro BoNT LC activity assays.
  • Figure 15 MALDI-TOF spectrum of biotinylated scrambled fragment. Sequence Lys(N3)-NGTLFNLSELRH-PEG 4 -Biotin. Expected m/z 2099.09, observed m/z 2098.06.
  • Figure16 List of hit sequences of epitope targeted screen. Beads were sequenced by Edman degredation and colors indicate similar sidechain residues to better illustrate homology, dashes indicate amino acids involved in the click cycle.
  • Figure 17 Click cyclized BoNT LC inhibitor (lnh-1) for target-guided screen. Sequence Dab(DNP)-R-[Lys(N3)-T-Dab-Pra]-L-Lys(Biotin)-Lys(N3). Expected m/z 1510.77, observed m/z 151 0.90.
  • Figure 18 Divalent Inhibitor (lnh-2) with PEG 4 linker. Sequence NH 2 - Dab(DNP)-R-[Lys(N3)-T-Dab-Pra]-L-Lys(Biotin) - T z 4-PEG 4 -[Pra-NYRWL-Lys(N3)]. Expected m/z 2801 .38, observed m/z 2799.45.
  • Figure 19 Single point sandwich ELISA comparing BoNT ligand variants. Peptides were immobilized on neutravidin resin at 1 ⁇ concentration and blocked in 3% BSA for 3 hours. Bound ligands were incubated with 50 nM BoNT LC- GST conjugate or buffer blank for three hours. ELISAs were probed with anti-GST- HRP mAb as detailed in protocols and developed.
  • Figure 20 Divalent Inhibitor with g-Aib-l linker and STP (lnh-2-STP).
  • Figure 21 Neurite outgrowth in iCell Neurons. Neurons 4 days after plating were stained according to the manufacturer's instructions with Neurite Outgrowth and Viability stains (Life Technologies), consisting of a Calcein viability stain (green) and a Dil C18 membrane stain (blue). All cells show a morphology consistent with neuronal outgrowth.
  • Figures 22A-22D Synaptic vesicle recycling in iCell Neurons. FM1 -43 stain (yellow) and nuclear stains (red) on live neurons after 15 days post-plating.
  • Figure 22A FM1 -43 labeled control cells, no depolarization
  • Figure 22B FM1 -43 labeled BoNT intoxicated cells, after depolarization
  • Figure 22C FM1 -43 labeled control cells, after depolarization
  • Figure 22D Unlabeled BoNT intoxicated cells. All labeling and depolarization is described in the SI procedures.
  • Figure 23 Image analysis of synaptic vesicle intensity. Images were analyzed by ImageJ. A watershed analysis was used to find the edges of neuron cell bodies in the transmission channel and allocate a given intercellular area to each cell. These areas were then mapped onto the FM1 -43 layer and puncta were counted in each area using the PunctaAnalyzer package while ignoring the previously identified cell bodies to find only synaptic vesicle puncta along neurites. The puncta count for each cell was averaged over two wells with two fields of view per well.
  • Figure 24 Evaluation of cytosolic delivery of STP with polar cargo.
  • Sequence of peptide is Cy5-DBCO-Lys(N3)-pliylrllrGqf.
  • Cells were treated at 1 ⁇ concentration for 30 minutes. After incubation the cells were washed once with neuronal medium and 2x with HBSS. One final wash was given with the suggested dilution of NucBlue Live Readyprobe (Life Technologies) in order to visualize the cell nuclei.
  • the capture agent that specifically binds botulinum neurotoxin serotype A and inhibits its ability to cleave SNAP-25 in neurons.
  • the capture agent comprises at least two ligands. One of the two ligands specifically binds to the enzymatic active site located on the light chain of botulinum neurotoxin serotype A and the other ligand binds at distinct location on the botulinum neurotoxin serotype A protein.
  • the second binding site is within 3-1 0 angstroms from the first binding site.
  • the ligand that binds to the second binding site is able to specifically bind the occluded conformation of the botulinum neurotoxin serotype A holotoxin.
  • the second binding site is also on the light chain of botulinum neurotoxin serotype A.
  • an anchor ligand is chosen that binds to the enzyme active site of botulinum neurotoxin serotype A protein. This enzyme active site is located on the light chain of the protein. According to certain embodiments, the anchor ligand inhibits the activity of the enzyme active site of botulinum neurotoxin serotype A protein. According to some embodiments, the anchor protein inhibits the activity of botulinum neurotoxin serotype A protein at an inhibition constant of between 1 0 and 1 000 nM. According to other embodiments, the inhibition constant is between 1 0 and 200 nM. According to other embodiments, the inhibition constant is between 30 and 1 00 nM, 50 and 80 nM or 65 and 75 nM. According to certain embodiments, the inhibition constant is about 70 nM.
  • a secondary ligand is chosen that also binds to the botulinum neurotoxin serotype A protein.
  • the secondary ligand is able to bind the occluded conformation of the botulinum neurotoxin serotype A holotoxin.
  • the secondary ligand binds to an epitope close enough to the binding site of the anchor ligand that a linker can be provided to connect the two ligands.
  • the secondary ligand is chosen as a result of screening a combinatorial library.
  • a linker is chosen that connects the two ligands.
  • the linker is rigid and similar in length to the distance between at least one portion of the two ligands when they are bound to the botulinum neurotoxin serotype A protein.
  • the portions of the ligands are the N- or C- termini.
  • the linker is about the length equal to the root mean square average separation of the two binding sites.
  • the linker is chosen as a result of screening a combinatorial linker library.
  • capture agent of the invention refers to synthetic protein-catalyzed capture agents which bind botulinum neurotoxin serotype A, as described herein.
  • Amino refers to the -N H 2 radical.
  • Cyano refers to the -CN radical.
  • Niro refers to the -NO 2 radical.
  • Alkyi refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, which is saturated or unsaturated ⁇ i.e., contains one or more double and/or triple bonds), having from one to twelve carbon atoms (C1 -C12 alkyi), preferably one to eight carbon atoms (d-Cs alkyi) or one to six carbon atoms (C1 -C6 alkyi), and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl,
  • Alkylene or "alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, which is saturated or unsaturated ⁇ i.e., contains one or more double and/or triple bonds), and having from one to twelve carbon atoms, e.g., methylene, ethylene, propylene, n-butylene, ethenylene, propenylene, n-butenylene, propynylene, n-butynylene, and the like.
  • the alkylene chain is attached to the rest of the molecule through a single or double bond and to the radical group through a single or double bond.
  • the points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain may be optionally substituted.
  • Alkoxy refers to a radical of the formula -OR a where R a is an alkyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted.
  • an alpha amino carbonyl is part of a cyclic moiety (e.g., peptide) where the carbonyl is within the ring and the amino (NR a R a ) is exocyclic.
  • alpha aminocarbonyl is useful for Edman degradation of cyclic peptides.
  • Alkylamino refers to a radical of the formula -NH R a or -NR a R a where each R a is, independently, an alkyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkylamino group may be optionally substituted.
  • Thioalkyl refers to a radical of the formula -SR a where R a is an alkyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, a thioalkyl group may be optionally substituted.
  • Aryl refers to a hydrocarbon ring system radical comprising hydrogen, 6 to 1 8 carbon atoms and at least one aromatic ring.
  • the aryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems.
  • Aryl radicals include, but are not limited to, aryl radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene.
  • Aralkyl refers to a radical of the formula -R b -R c where R b is an alkylene chain as defined above and R c is one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl and the like. Unless stated otherwise
  • an aralkyl group may be optionally substituted.
  • Cycloalkyl or “carbocyclic ring” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from three to fifteen carbon atoms, preferably having from three to ten carbon atoms, and which is saturated or unsaturated and attached to the rest of the molecule by a single bond.
  • Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Polycyclic radicals include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1 ]heptanyl, and the like. Unless otherwise stated specifically in the specification, a
  • cycloalkyl group may be optionally substituted.
  • Cycloalkylalkyl refers to a radical of the formula -R b d where R b is an alkylene chain as defined above and R d is a cycloalkyi radical as defined above. Unless stated otherwise specifically in the specification, a cycloalkylalkyl group may be optionally substituted.
  • fused refers to any ring structure described herein which is fused to an existing ring structure in the compounds of the invention.
  • the fused ring is a heterocyclyl ring or a heteroaryl ring
  • any carbon atom on the existing ring structure which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring may be replaced with a nitrogen atom.
  • Halo or "halogen” refers to bromo, chloro, fluoro or iodo.
  • Haloalkyl refers to an alkyl radical, as defined above, that is
  • halo radicals as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1 ,2-difluoroethyl,
  • haloalkyl group may be optionally substituted.
  • Heterocyclyl or “heterocyclic ring” refers to a stable 3- to 1 8-membered non-aromatic ring radical which consists of two to twelve carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
  • the heterocyclyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be partially or fully saturated.
  • heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1 ,3]dithianyl, decahydroisoquinolyl, imidazolinyl , imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl , pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl,
  • a heterocyclyl group may be optionally substituted.
  • "/V-heterocyclyl” refers to a heterocyclyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a nitrogen atom in the heterocyclyl radical. Unless stated otherwise specifically in the specification, a /V-heterocyclyl group may be optionally substituted.
  • Heterocyclylalkyl refers to a radical of the formula -R b R e where R b is an alkylene chain as defined above and R e is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the
  • heterocyclyl may be attached to the alkyl radical at the nitrogen atom. Unless stated otherwise specifically in the specification, a heterocyclylalkyl group may be optionally substituted.
  • Heteroaryl refers to a 5- to 1 4-membered ring system radical
  • heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized ; the nitrogen atom may be optionally quaternized. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl,
  • N-heteroaryl refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical. Unless stated otherwise specifically in the specification, an N-heteroaryl group may be optionally substituted.
  • Heteroarylalkyl refers to a radical of the formula -RbRf where Rb is an alkylene chain as defined above and Rf is a heteroaryl radical as defined above. Unless stated otherwise specifically in the specification, a heteroarylalkyl group may be optionally substituted.
  • substituted means any of the above groups (e.g., alkyl, alkylene, alkoxy, alkylamino, aminocarbonyl, oc-aminocarbonyl, oc- amidocarbonyl , thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, /V-heterocyclyl, heterocyclylalkyl, heteroaryl, /V-heteroaryl and/or heteroarylalkyl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, CI, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioalky
  • alkylarylamines diarylamines, N-oxides, imides, and enamines
  • a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl groups; and other heteroatoms in various other groups.
  • Substituted also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple- bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
  • a higher-order bond e.g., a double- or triple- bond
  • nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
  • substituted includes any of the above groups in which one or more hydrogen atoms are replaced
  • R g and Rh are the same or different and independently hydrogen, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl , heterocyclyl, /V-heterocyclyl,
  • heterocyclylalkyl heteroaryl, /V-heteroaryl and/or heteroarylalkyl .
  • "Substituted” further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, /V-heterocyclyl, heterocyclylalkyl, heteroaryl, N- heteroaryl and/or heteroarylalkyl group.
  • each of the foregoing substituents may also be optionally substituted with one or more of the above substituents.
  • Prodrug is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound of the invention.
  • prodrug refers to a metabolic precursor of a
  • a prodrug may be inactive when administered to a subject in need thereof, but is converted in vivo to an active compound of the invention.
  • Prodrugs are typically rapidly transformed in vivo to yield the parent compound of the invention, for example, by hydrolysis in blood.
  • the prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, Bundgard, H., Design of Prodrugs (1 985), pp. 7-9, 21 -24 (Elsevier, Amsterdam)).
  • a discussion of prodrugs is provided in Higuchi, T., et al., A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, Ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1 987.
  • prodrug is also meant to include any covalently bonded carriers, which release the active compound of the invention in vivo when such prodrug is administered to a mammalian subject.
  • Prodrugs of a compound of the invention may be prepared by modifying functional groups present in the compound of the invention in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound of the invention.
  • Prodrugs include compounds of the invention wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the compound of the invention is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively.
  • Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol or amide derivatives of amine functional groups in the compounds of the invention and the like.
  • the invention disclosed herein is also meant to encompass all pharmaceutically acceptable peptides of structure (I) or ( ⁇ ) being isotopically- labelled by having one or more atoms replaced by an atom having a different atomic mass or mass number.
  • isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H, 3 H, 1 1 C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 31 P, 32 P, 35 S, 18 F, 36 CI, 123 l, and 125 l, respectively.
  • radiolabeled compounds could be useful to help determine or measure the effectiveness of the compounds, by characterizing, for example, the site or mode of action, or binding affinity to pharmacologically important site of action.
  • Certain isotopically-labelled peptides of the invention for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
  • the radioactive isotopes tritium, i.e. 3 H , and carbon-14, i.e. 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
  • Substitution with heavier isotopes such as deuterium, i.e. 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
  • Isotopically-labeled peptides can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Preparations and Examples as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
  • the invention disclosed herein is also meant to encompass the in vivo metabolic products of the disclosed peptides. Such products may result from, for example, the oxidation, reduction, hydrolysis, amidation, esterification, and the like of the administered compound, primarily due to enzymatic processes.
  • the invention includes compounds produced by a process comprising administering a compound of this invention to a mammal for a period of time sufficient to yield a metabolic product thereof.
  • Such products are typically identified by administering a radiolabelled compound of the invention in a detectable dose to an animal, such as rat, mouse, guinea pig, monkey, or to human, allowing sufficient time for metabolism to occur, and isolating its conversion products from the urine, blood or other biological samples.
  • “Mammal” includes humans and both domestic animals such as laboratory animals and household pets (e.g., cats, dogs, swine, cattle, sheep, goats, horses, rabbits), and non-domestic animals such as wildlife and the like.
  • mutant refers to a protein that has high homology to a wild-type amino acid sequence, but not 1 00% identity with the wild-type amino acid sequence. High homology associated with mutants or variants is higher than 95, 96, 97, 98 or 99% but less than 1 00%. In certain embodiments, a mutant or variant differs from a wild-type sequence at 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 1 0 amino acids.
  • sequence of BoNT serotype A refers to the amino acid sequence shown below.
  • the above sequence is the full sequence of the holoenzyme.
  • This holoenzyme is cleaved into light chain and heavy chain peptides.
  • the light chain is made up of amino acids 1 -448 above and the heavy chain is made of of amino acids 449-1 291 .
  • Optional or “optionally” means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not.
  • optionally substituted aryl means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.
  • “Pharmaceutically acceptable carrier, diluent or excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
  • “Pharmaceutically acceptable salt” includes both acid and base addition salts.
  • “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4- acetamidobenzoic acid, camphoric acid, camphor-1 0-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1 ,2-disulfonic acid, ethanesulfonic acid, 2- hydroxy
  • “Pharmaceutically acceptable base addition salt” refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts.
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, /V-ethylpiperidine, polyamine resins and the like.
  • Particularly preferred organic bases are is
  • the compounds (peptides) of the invention, or their pharmaceutically acceptable salts may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined , in terms of absolute stereochemistry, as (R)- or ( S)- or, as (D)- or (L)- for amino acids.
  • the present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms.
  • Optically active (+) and (-) , (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization.
  • Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography ( H PLC) .
  • H PLC high pressure liquid chromatography
  • (D)-amino acids also referred to as D-amino acids
  • (L)-amino acids are referred to in upper case letters (e.g. L-valine or valine is referred to as "V")
  • Glycine is non-chiral and is referred to as "G”.
  • a “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable.
  • the present invention contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are nonsuperimposeable mirror images of one another.
  • a "tautomer” refers to a proton shift from one atom of a molecule to another atom of the same molecule.
  • the present invention includes tautomers of any said compounds.
  • Often crystallizations produce a solvate of the compound of the invention.
  • the term "solvate” refers to an aggregate that comprises one or more molecules of a compound of the invention with one or more molecules of solvent.
  • the solvent may be water, in which case the solvate may be a hydrate. Alternatively, the solvent may be an organic solvent.
  • the compounds of the present invention may exist as a hydrate, including a monohydrate, dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate and the like, as well as the corresponding solvated forms.
  • the compound of the invention may be true solvates, while in other cases, the compound of the invention may merely retain adventitious water or be a mixture of water plus some adventitious solvent.
  • capture agent refers to a composition that comprises one or more target-binding moieties and which specifically binds to a target protein via those target-binding moieties. Each target-binding moiety exhibits binding affinity for the target protein, either individually or in
  • each target-binding moiety binds to the target protein via one or more non-covalent interactions, including for example hydrogen bonds, hydrophobic interactions, and van der Waals interactions.
  • a capture agent may comprise one or more organic molecules, including for example polypeptides, peptides,
  • a capture agent is a protein catalyzed capture agent (PCC).
  • PCC protein catalyzed capture agent
  • epitope refers to a distinct molecular surface of a protein (e.g., the BoNT serotype A protein).
  • the epitope is a polypeptide and it can act on its own as a finite sequence of 1 0-40 amino acids.
  • at least two epitopes are bound.
  • the first epitope involves the enzymatic active site of the epitope BoNT serotype A.
  • the anchor ligand binds this enzymatic active site with high affinity so that its activity is inhibited.
  • the second epitope is a portion of the BoNT serotype A holotoxin that is solvent exposed in the occluded conformation.
  • this epitoipe can be amino acids 1 66- 1 79 of the BoNT serotype A (light chain).
  • polypeptide amino acid sequence comprising a polymer of amino acid residues.
  • the terms apply to amino acid polymers in which one or more amino acid residues is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers.
  • amino acid refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids, and isomers thereof.
  • Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline,
  • amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium.
  • R groups e.g., norleucine
  • modified peptide backbones but retain the same basic chemical structure as a naturally occurring amino acid.
  • amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid. Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the lU PAC- IU B Biochemical Nomenclature Commission.
  • non-natural amino acid refers to an amino acid that is different from the twenty naturally occurring amino acids (alanine, arginine, glycine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, serine, threonine, histidine, lysine, methionine, proline, valine, isoleucine, leucine, tyrosine, tryptophan, phenylalanine) in its side chain functionality.
  • amino acids alanine, arginine, glycine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, serine, threonine, histidine, lysine, methionine, proline, valine, isoleucine, leucine, tyrosine, tryptophan, phenylalanine
  • the non-natural amino acid can be a close analog of one of the twenty natural amino acids, or it can introduce a completely new functionality and chemistry, as long as the hydrophobicity of the non-natural amino acid is either equivalent to or greater than that of the natural amino acid.
  • the non-natural amino acid can either replace an existing amino acid in a protein (substitution), or be an addition to the wild type sequence (insertion).
  • the incorporation of non-natural amino acids can be accomplished by known chemical methods including solid-phase peptide synthesis or native chemical ligation, or by biological methods.
  • Non- natural amino acids can include 2-aminoisobutyric acid (Aib) and
  • the terms "specific binding,” “selective binding,” “selectively binds,” or “specifically binds” as used herein refer to capture agent binding to an epitope on a predetermined antigen.
  • the capture agent binds with an affinity (KD) of approximately less than 1 0 "5 M, such as approximately less than 1 0 "6 M, 1 0 "7 M, 1 0 “8 M, 1 0 “9 M or 1 0 "1 0 M or even lower.
  • K D refers to the dissociation equilibrium constant of a particular capture agent-antigen interaction.
  • the capture agents of the invention bind to BoNT serotype A protein with a dissociation equilibrium constant (KD) of less than approximately 1 0 "6 M, 1 0 "7 M, 1 0 "8 M, 1 0 "9 M or 1 0 "1 0 M or even lower, for example, as determined using surface plasmon resonance (SPR) technology in a Biacore instrument using the capture agent as the ligand and the BoNT serotype A protein as the analyte, and bind to a BoNT serotype A protein with an affinity corresponding to a K D that is at least ten-fold lower, such as at least 1 00 fold lower, for instance at least 1 000 fold lower, such as at least 1 0,000 fold lower, for instance at least 1 00,000 fold lower than its affinity for binding to a non-specific antigen (e.g., BSA, casein
  • a non-specific antigen e.
  • the amount with which the affinity is lower is dependent on the K D of the capture agent, so that when the K D of the capture agent is very low (that is, the capture agent is highly specific), then the amount with which the affinity for the antigen is lower than the affinity for a non-specific antigen may be at least 1 0,000 fold.
  • k d (sec -1 ) as used herein refers to the dissociation rate constant of a particular capture agent-antigen interaction. Said value is also referred to as the k 0 ff value.
  • k a (M ⁇ 1 xsec ⁇ 1 ) as used herein refers to the association rate constant of a particular capture agent-antigen interaction.
  • KD (M) as used herein refers to the dissociation equilibrium constant of a particular capture agent-antigen interaction.
  • K A (M ⁇ 1 ) as used herein refers to the association equilibrium constant of a particular capture agent-antigen interaction and is obtained by dividing the k a by the kd.
  • a "pharmaceutical composition” refers to a formulation of a compound of the invention and a medium generally accepted in the art for the delivery of the biologically active compound to mammals, e.g., humans.
  • a medium includes all pharmaceutically acceptable carriers, diluents or excipients therefor.
  • condition refers generally to a disease, event, or a change in health status.
  • a change in health status may be associated with a particular disease or event, in which case the change may occur simultaneously with or in advance of the disease or event. In those cases where the change in health status occurs in advance of a disease or event, the change in health status may serve as a predictor of the disease or event. For example, a change in health status may be an alteration in the expression level of a particular gene associated with a disease or event. Alternatively, a change in health status may not be associated with a particular disease or event.
  • the condition is botulism or botulin toxin poisoning.
  • treat generally refers to preventing a condition or event, slowing the onset or rate of
  • an "effective amount” or “therapeutically effective amount” as used herein refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result.
  • a therapeutically effective amount of a capture agent may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the capture agent to elicit a desired response in the individual.
  • antibody refers to a protein of the kind that is produced by activated B cells after stimulation by an antigen and can bind specifically to the antigen promoting an immune response in biological systems.
  • Full antibodies typically consist of four subunits including two heavy chains and two light chains.
  • the term antibody includes natural and synthetic antibodies, including but not limited to monoclonal antibodies, polyclonal antibodies or fragments thereof.
  • Exemplary antibodies include IgA, IgD, IgGI, lgG2, lgG3, Ig M and the like.
  • Exemplary fragments include Fab, Fv, Fab', F(ab') 2 and the like.
  • a monoclonal antibody is an antibody that specifically binds to and is thereby defined as complementary to a single particular spatial and polar organization of another biomolecule which is termed an "epitope." In some forms, monoclonal antibodies can also have the same structure.
  • a polyclonal antibody refers to a mixture of different monoclonal antibodies. In some forms, polyclonal antibodies can be a mixture of monoclonal antibodies where at least two of the monoclonal antibodies binding to a different antigenic epitope. The different antigenic epitopes can be on the same target, different targets, or a combination.
  • Antibodies can be prepared by techniques that are well known in the art, such as immunization of a host and collection of sera (polyclonal) or by preparing continuous hybridoma cell lines and collecting the secreted protein (monoclonal).
  • stable as used herein with regard to a capture agent protein catalyzed capture agent or pharmaceutical formulation thereof refers to the agent or formulation retaining structural and functional integrity for a sufficient period of time to be utilized in the methods described herein.
  • sequence identity/similarity values refer to the value obtained using the BLAST 2.0 suite of programs using default parameters (Altschul, et al., (1 997) Nucleic Acids Res. 25:3389-402).
  • BLAST searches assume that proteins can be modeled as random sequences. However, many real proteins comprise regions of nonrandom sequences, which may be homopolymeric tracts, short-period repeats, or regions enriched in one or more amino acids. Such low-complexity regions may be aligned between unrelated proteins even though other regions of the protein are entirely dissimilar. A number of low-complexity filter programs can be employed to reduce such low- complexity alignments.
  • the SEG Wioten and Federhen, (1 993) Comput. Chem. 1 7:149-63) and XN U (Claverie and States, (1 993) Comput. Chem. 1 7: 1 91 -201 ) low-complexity filters can be employed alone or in combination.
  • sequence identity in the context of two nucleic acid or polypeptide sequences includes reference to the residues in the two sequences, which are the same when aligned for maximum correspondence over a specified comparison window.
  • sequence identity When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. Where sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution.
  • Sequences which differ by such conservative substitutions, are said to have "sequence similarity" or "similarity.” Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non- conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1 . The scoring of conservative substitutions is calculated, e.g., according to the algorithm of Meyers and Miller, (1 988)
  • percentage of sequence identity means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 1 00 to yield the percentage of sequence identity.
  • polynucleotide sequences means that a polynucleotide comprises a sequence that has between 50-1 00% sequence identity, preferably at least 50% sequence identity, preferably at least 60% sequence identity, preferably at least 70%, more preferably at least 80%, more preferably at least 90% and most preferably at least 95%, compared to a reference sequence using one of the alignment programs described using standard parameters.
  • sequence identity preferably at least 50% sequence identity, preferably at least 60% sequence identity, preferably at least 70%, more preferably at least 80%, more preferably at least 90% and most preferably at least 95%
  • Substantial identity of amino acid sequences for these purposes normally means sequence identity of between 55-1 00%, preferably at least 55%, preferably at least 60%, more preferably at least 70%, 80%, 90% and most preferably at least 95%.
  • N3 and Pra moieties together represent a Tz4 or a Tz5 linkage.
  • Antibodies are currently the default detection agent for use in diagnostic platforms. However, antibodies possess several disadvantages, including high cost, poor stability, and, in many cases, lack of proper characterization and high specificity.
  • the ideal replacement for use in diagnostic assays should be synthetic, stable to a range of thermal and chemical conditions, and display high affinity and specificity for the target of interest.
  • a high quality monoclonal antibody possesses low-nanomolar affinity and high target specificity.
  • structural and genetic analyses of the antigen recognition surface have shown that the majority of the molecular diversity of the variable loops is contained in a single highly variable loop (CDR- H3). In humans, this loop ranges in size from 1 -35 residues (1 5 on average), can adopt a wide range of structural conformations, and is responsible for most of the interactions with the antigen. The other five loops are significantly less diverse and adopt only a handful of conformations. This suggests that a carefully selected "anchor" peptide can dominate the mode and strength of the interaction between a capture agent and its target protein. It also suggests that other peptide components, while providing only modest contributions to the total interaction energy, can supply important scaffolding features and specificity elements.
  • In situ click chemistry is a technique in which a small molecule enzymatic inhibitor is separated into two moieties, each of which is then expanded into a small library - one containing acetylene functionalities, and the other containing azide groups.
  • the enzyme itself then assembles the 'best fit' inhibitor from these library components by selectively promoting 1 ,3-dipolar cycloaddition between the acetylene and azide groups to form a triazole linkage (the 'click' reaction).
  • the protein effectively plays the role of an extremely selective variant of the Cu(l) catalyst that is commonly used for such couplings.
  • the enzyme promotes the click reaction only between those library components that bind to the protein in the right orientation.
  • the resultant inhibitor can exhibit far superior affinity characteristics relative to the initial inhibitor that formed the basis of the two libraries.
  • Sequential in situ click chemistry extends the in situ click chemistry concept to enable the discovery of multiligand capture agents (see: USSN 201 00009896, incorporated herein by reference). This process was used previously to produce a triligand capture agent against the model protein carbonic anhydrase I I (CAM) . Sequential in situ click chemistry has several advantages. First, structural information about the protein target is replaced by the ability to sample a very large chemical space to identify the ligand components of the capture agent.
  • an initial ligand may be identified by screening the protein against a large (> 1 0 6 element) one-bead- one-compound (OBOC) peptide library, where the peptides themselves may be comprised of natural, non-natural, and/or artificial amino acids.
  • the resultant anchor ligand is then utilized in an in situ click screen, again using a large OBOC library, to identify a biligand binder.
  • a second advantage is that the process can be repeated, so that the biligand is used as an anchor to identify a triligand, and so forth.
  • the final capture agent can then be scaled up using relatively simple and largely automated chemistries, and it can be developed with a label, such as a biotin group, as an intrinsic part of its structure.
  • the present embodiment further generalizes the in situ click application to find a linker that links two ligands to a single protein. This method uses cooperative binding to make a capture ligand with higher affinity than either of its component ligands.
  • a stable, synthetic capture agent that specifically binds BoNT Serotype A, wherein the capture agent comprises a designed anchor ligand, a designed secondary ligand, optionally a designed tertiary ligand, and optionally a designed quarternary ligand, and wherein the ligands selectively bind BoNT Serotype A.
  • the capture agent specifically binds the enzymatic active site of BoNT Serotype A.
  • the capture agent specifically binds a site of BoNT Serotype A that is accessible on the occluded conformation of the holotoxin.
  • biligand BoNT Serotype A capture agents comprising two target-binding moieties.
  • the first target-binding moiety is referred to as an anchor ligand, and the second is referred to as a secondary ligand.
  • triligand and tetraligand capture agents wherein the third target-binding moiety is referred to as a tertiary ligand, and the fourth target- binding moiety is referred to as a quarternary ligand.
  • a target-binding moiety comprises one or more polypeptides or peptides.
  • a target-binding moiety comprises one or more peptides comprising D-amino acids, L-amino acids, and/or amino acids substituted with functional groups selected from the group consisting of substituted and unsubstituted alkyl, substituted and unsubstituted azido, substituted and unsubstituted alkynyl, substituted and unsubstituted biotinyl, substituted and unsubstituted azioalkyl, substituted and unsubstituted polyethyleneglycolyl, and substituted and unsubstituted 1 ,2,3-triazole.
  • the anchor ligand and secondary ligand are linked to one another via a covalent linkage to form a capture agent biligand.
  • the anchor ligand and secondary ligand are linked to one another via an amide bond or a 1 ,4-disubstituted-1 ,2,3-triazole linkage as shown below:
  • the 1 ,4-disubstituted - 1 ,2,3-triazole linkage may be formed by Cu-Catalyzed Azide/Alkyne Cycloaddition (CuAAC).
  • the anchor and secondary ligands are linked to one another by a Tz4 linkage having the following structure:
  • the anchor and secondary ligands are linked to one another by a Tz5 linkage having the following structure:
  • the tertiary and/or quarternary ligand is linked to the capture agent biligand by a covalent linkage, preferably via the secondary ligand in the biligand.
  • the tertiary ligand and the biligand and/or the quarternary ligand and the tertiary ligand are linked to one another by a Tz4 linkage.
  • the amide bond may be formed by coupling a carboxylic acid group and an amine group in the presence of a coupling agent (e.g., 0-(7-azabenzotriazol-1 -yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate (HATU), N-hydroxy-7-aza-benzotriazole (HOAt), or diisopropylethylamine (DIEA) in DMF).
  • a coupling agent e.g., 0-(7-azabenzotriazol-1 -yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate (HATU), N-hydroxy-7-aza-benzotriazole (HOAt), or diisopropylethylamine (DIEA) in DMF.
  • the capture agents provided herein are stable across a range of reaction conditions and/or storage times.
  • a capture agent that is "stable” as used herein maintains the ability to specifically bind to a target protein.
  • the capture agents provided herein are more stable than an antibody binding to the same target protein under one or more reaction and/or storage conditions.
  • the capture agents provided herein are more resistant to proteolytic degradation than an antibody binding to the same target protein.
  • the capture agents provided herein have a shelf-life of greater than six months, meaning that they are stable in storage for greater than six months. In certain of these embodiments, the capture agents have a shelf-life of one year or greater, two years or greater, or more than three years. In certain of these embodiments, the capture agents are stored as a lyophilized powder. In certain embodiments, the capture agents provided herein have a longer shelf-life than an antibody binding to the same target protein.
  • the capture agents provided herein are stable at temperatures ranging from about -80° to about 1 20°C. In certain of these
  • the capture agents are stable within a temperature range of -80° to - 40 °C; -40° to -20 °C; -20° to 0°C; 0° to 20 °C; 20° to 40 °C; 40° to 60 °C; 60° to 80 °C; and/or 80° to 120°C.
  • the capture agents provided herein are stable across a wider range of temperatures than an antibody binding to the same target protein, and/or remain stable at a specific temperature for a longer time period than an antibody binding to the same target protein.
  • the capture agents provided herein are stable at a pH range from about 3.0 to about 8.0. In certain embodiments, the range is about 4.0 to about 7.0. In certain embodiments, the range is about 7.0 to about 8.0.
  • the capture agents provided herein are stable in human serum for more than 1 2 hours. In certain of these embodiments, the capture agents are stable in human serum for more than 18 hours, more than 24 hours, more than 36 hours, or more than 48 hours. In certain embodiments, the capture agents provided herein are stable for a longer period of time in human serum than an antibody binding to the same target protein. In certain embodiments, the capture agents are stable as a powder for two months at a temperature of about 60 Q C.
  • the capture agents provided herein may comprise one or more detection labels, including for example biotin, copper-1 ,4,7,10- tetraazacyclododecane-1 ,4,7, 10-tetraacetic acid (copper- DOTA), 64 Cu DOTA, 68 Ga DOTA, 18 F, 64 Cu, 68 Ga, 89 Zr, 124 l, 86 Y, 94m Tc, 110m ln, 11 C, 76 Br, 123 l, 131 l, 67 Ga, 1 11 ln and 99m Tc, or other radiolabeled products that may include gamma emitters, proton emitters, positron emitters, tritium, or covered tags detectable by other methods (i.e., gadolinium) among others.
  • the detection label is 18 F.
  • the capture agents may be modified to be used as imaging agents.
  • the imaging agents may be used as diagnostic agents.
  • the capture agents provided herein may be modified to obtain a desired chemical or biological activity.
  • desired chemical or biological activities include, without limitation, improved solubility, stability, bioavailability, detectability, or reactivity.
  • specific modifications that may be introduced to a capture agent include, but are not limited to, cyclizing the capture agent through formation of a disulfide bond; modifying the capture agent with other functional groups or molecules.
  • a capture agent may be synthesized to bind to non-canonical or non-biological epitopes on proteins, thereby increasing their versatility.
  • the capture agent may be modified by modifying the synthesis blocks of the target-binding moieties before the coupling reaction.
  • WO 2012/106671 WO 2013/033561
  • WO 2013/009869 WO 2014/074907
  • the capture agent production methods disclosed herein begin with identification of a short-chain anchor peptide, then proceed by adding additional covalently coupled peptide ligands via a process that is promoted by the target protein.
  • the specificity and inhibitory potency of the final multiligand capture agent are augmented by the peripheral peptide ligands.
  • a capture agent of the invention can be detectably labeled, then contacted with the solution, and thereafter formation of a complex between the capture agent and the BoNT Serotype A target can be detected.
  • a fluorescently labeled capture agent can be used for in vitro BoNT Serotype A detection assays, wherein the capture agent is added to a solution to be tested for BoNT Serotype A under conditions allowing binding to occur.
  • the complex between the fluorescently labeled capture agent and the BoNT Serotype A target can be detected and quantified by, for example, measuring the increased fluorescence polarization arising from the complex-bound peptide relative to that of the free peptide.
  • a sandwich-type "ELISA" assay can be used, wherein a capture agent is immobilized on a solid support such as a plastic tube or well, then the solution suspected of containing BoNT Serotype A is contacted with the immobilized binding moiety, non-binding materials are washed away, and complexed polypeptide is detected using a suitable detection reagent for recognizing BoNT Serotype A.
  • capture agents of the invention can be immobilized on a solid substrate such as a chromatographic support or other matrix material, then the immobilized binder can be loaded or contacted with the solution under conditions suitable for formation of a capture agent/BoNT Serotype A complex.
  • the non-binding portion of the solution can be removed and the complex can be detected, for example, using an anti-BoNT Serotype A antibody, or an anti-binding polypeptide antibody, or the BoNT Serotype A can be released from the binding moiety at appropriate elution conditions.
  • a particularly preferred use for the capture agents of the invention is for creating visually readable images of BoNT Serotype A or BoNT Serotype A- expressing cells in a biological fluid.
  • the BoNT Serotype A capture agents disclosed herein can be converted to imaging reagents by conjugating the capture agents with a label appropriate for diagnostic detection.
  • a capture agent exhibiting much greater specificity for BoNT Serotype A than for other proteins is conjugated or linked to a label appropriate for the detection methodology to be employed.
  • the capture agent can be conjugated with or without a linker to a paramagnetic chelate suitable for Magnetic Resonance Imaging (MRI), with a radiolabel suitable for x-ray, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) or scintigraphic imaging (including a chelator for a radioactive metal), with an ultrasound contrast agent (e.g., a stabilized microbubble, a microballoon, a microsphere or what has been referred to as a gas filled "liposome”) suitable for ultrasound detection, or with an optical imaging dye.
  • MRI Magnetic Resonance Imaging
  • PET Positron Emission Tomography
  • SPECT Single Photon Emission Computed Tomography
  • scintigraphic imaging including a chelator for a radioactive metal
  • an ultrasound contrast agent e.g., a stabilized microbubble, a microballoon, a microsphere or what has been referred to as a gas filled "liposome
  • one or more peptides or constructs of the invention can be conjugated with for example, avidin, biotin, or an antibody or antibody fragment that will bind the detectable label or radiotherapeutic.
  • BoNT Serotype A capture agents described herein can advantageously be conjugated with a paramagnetic metal chelate in order to form a contrast agent for use in MRI.
  • Preferred paramagnetic metal ions have atomic numbers 21 -29, 42, 44, or 57-83. This includes ions of the transition metal or lanthanide series which have one, and more preferably five or more, unpaired electrons and a magnetic moment of at least 1 .7 Bohr magneton.
  • Preferred paramagnetic metals include, but are not limited to, chromium (II I), manganese (II), manganese (III), iron (II), iron (I II), cobalt (II), nickel (II), copper (II), praseodymium (II I), neodymium (III), samarium (III), gadolinium (III), terbium (III), dysprosium (III), holmium (III), erbium (III), europium (III) and ytterbium (III), chromium (III), iron (III), and gadolinium (III).
  • the trivalent cation, Gd 3+ is particularly preferred for MRI contrast agents, due to its high relaxivity and low toxicity, with the further advantage that it exists in only one biologically
  • Gd(ll l) chelates have been used for clinical and radiologic MR applications since 1988, and approximately 30% of MRI exams currently employ a gadolinium-based contrast agent.
  • the paramagnetic metal chelator is a molecule having one or more polar groups that act as a ligand for, and complex with, a paramagnetic metal.
  • Suitable chelators are known in the art and include acids with methylene phosphonic acid groups, methylene carbohydroxamine acid groups, carboxyethylidene groups, or carboxymethylene groups.
  • chelators include, but are not limited to, diethylenetriaminepentaacetic acid (DTPA), 1 ,4,7,10-tetraazacyclo-tetradecane- 1 ,4,7,1 0-tetraacetic acid (DOTA), 1 -substituted 1 ,4,7,-tricarboxymethyl-1 ,4,7,1 0- teraazacyclododecane (D03A), ethylenediaminetetraacetic acid (EDTA), and 1 ,4,8,1 1 -tetra-azacyclotetradecane-1 ,4,8,1 1 -tetraacetic acid (TETA).
  • DTPA diethylenetriaminepentaacetic acid
  • DDA 1 -substituted 1 ,4,7,-tricarboxymethyl-1 ,4,7,1 0- teraazacyclododecane
  • EDTA ethylenediaminetetraacetic acid
  • TETA TETA
  • Additional chelating ligands are ethylene bis-(2-hydroxy-phenylglycine) (EHPG), and derivatives thereof, including 5-CI-EHPG, 5-Br-EHPG, 5-Me-EHPG, 5-t-Bu-EHPG, and 5-sec-Bu-EHPG; benzodiethylenetriamine pentaacetic acid (benzo-DTPA) and derivatives thereof, including dibenzo-DTPA, phenyl-DTPA, diphenyl-DTPA, benzyl- DTPA, and dibenzyl DTPA; bis-2 (hydroxybenzyl)-ethylene-diaminediacetic acid (HBED) and derivatives thereof; the class of macrocyclic compounds which contain at least 3 carbon atoms, more preferably at least 6, and at least two heteroatoms (O and/or N), which macrocyclic compounds can consist of one ring, or two or three rings joined together at the hetero ring elements, e.g., benzo-DOTA, dibenzo-DOTA,
  • MECAM MECAM
  • a preferred chelator for use in the present invention is DTPA, and the use of D03A is particularly preferred.
  • Examples of representative chelators and chelating groups contemplated by the present invention are described in WO 98/18496, WO 86/06605, WO 91 /03200, WO 95/28179, WO 96/23526, WO 97/36619,
  • PCT/US98/01473, PCT/US98/201 82 and U.S. Pat. No. 4,899,755, U.S. Pat. No. 5,474,756, U.S. Pat. No. 5,846,519 and U.S. Pat. No. 6,143,274, all of which are hereby incorporated by reference.
  • the chelator of the MRI contrast agent is coupled to the BoNT Serotype A capture agent.
  • the positioning of the chelate should be selected so as not to interfere with the binding affinity or specificity of the BoNT Serotype A capture agent.
  • the chelate also can be attached anywhere on the capture agent.
  • the BoNT Serotype A capture agent can be bound directly or covalently to the metal chelator (or other detectable label), or it can be coupled or conjugated to the metal chelator using a linker, which can be, without limitation, amide, urea, acetal, ketal, double ester, carbonyl, carbamate, thiourea, sulfone, thioester, ester, ether, disulfide, lactone, imine, phosphoryl, or phosphodiester linkages; substituted or unsubstituted saturated or unsaturated alkyl chains; linear, branched, or cyclic amino acid chains of a single amino acid or different amino acids (e.g., extensions of the N- or C-terminus of the BoNT Serotype A binding moiety); derivatized or underivatized polyethylene glycols (PEGs), polyoxyethylene, or polyvinylpyridine chains; substituted or unsubstituted polyamide chains; derivatized or underivat
  • the molecular weight of the linker is less than 100.
  • biodegradable functionalities can include ester, double ester, amide, phosphoester, ether, acetal, and ketal functionalities.
  • BoNT Serotype A binding moiety can be linked through an N- or C-terminus via an amide bond, for example, to a metal coordinating backbone nitrogen of a metal chelate or to an acetate arm of the metal chelate itself.
  • the present disclosure contemplates linking of the chelate on any position, provided the metal chelate retains the ability to bind the metal tightly in order to minimize toxicity.
  • MRI contrast reagents prepared according to the disclosures herein can be used in the same manner as conventional MRI contrast reagents.
  • Certain MR techniques and pulse sequences can be preferred to enhance the contrast of the site to the background blood and tissues. These techniques include (but are not limited to), for example, black blood angiography sequences that seek to make blood dark, such as fast spin echo sequences (Alexander, A. et al., 1998. Magn. Reson. Med., 40: 298-31 0) and flow-spoiled gradient echo sequences (Edelman, R. et al., 1990. Radiology, 177: 45-50).
  • BoNT Serotype A capture agents disclosed herein to inhibit the activity of BoNT Serotype A in vitro or in vivo.
  • the BoNT Serotype A capture agents disclosed herein can be used to treat botulinism or improve one or more symptoms associated with
  • the BoNT Serotype A capture agents disclosed herein are able to bind the occluded conformation of the BoNT Serotype A holotoxin. This occluded conformation is removed when BoNT Serotype A is translocated inside of a cell, for example a neuron. This allows access for inhibitors to the enzymatic active site of BoNT Serotype A.
  • Serotype A capture agent binds to the protein before it is internalized into a cell, providing access for the active site binding portion of the capture agent when it is transferred into the cell along with the BoNT Serotype A protein.
  • Example 1 Screening strategy for Botulinum Neurotoxin-specific liqand.
  • a macrocyclic peptide ligand was developed (lnh-1 , Figures 6 and 7) that is a substrate mimic for BoNT. lnh-1 binds to the active site with a approximatlely 70 nM binding affinity (kp) and similar inhibition constant.
  • An all synthetic in situ click epitope targeting approach (shown in Figure 1 ) was employed to identify a second peptide macrocycle (L2, Figures 8 and 9) that binds to a site a few angstroms away in the folded protein structure from the active site. L2 exhibits a ko of approximately 80 nM, but no inhibitory effects.
  • an in situ click screen was utilized, promoted by the BoNT LC, to identify a linear peptide that connects the two macrocycles
  • the final divalent ligand (shown in Figure 2).
  • the final divalent ligand (lnh-2, Figure 1 0) inhibits the BoNT LC with an IC50 of 1 65 ⁇ 15 pM.
  • lnh-2 is also carried into neuronal cells by BoNT itself, and inhibits the holotoxin in live cells. This technique provides a potentially general route for the development of peripheral and active site binders from naive libraries for combination through in situ click target-guided synthesis.
  • the epitope (BoNT LC residues 166-179, Figure 14) was synthesized with an N-terminal azidolysine and a C-terminal biotin and was screened against a 1 .1 M element library of macrocyclic 5-mer peptides synthesized on Tentagel resin substituted with an N-terminal propargylglycine (shown in Figure 2) and anti- screened against a scrambled version of the same epitope ( Figure 15).
  • This constrained macrocyclic peptide library was used due to the increased stability and decreased entropic penalty of binding relative to linear peptides.
  • Variants of this ligand were synthesized with a fluorescein dye for fluorescence polarization, a biotin for binding assays and a spontaneously translocating peptide (STP) reported for the delivery of polar cargo to the cytosol ( Figure 20).
  • iCell neurons After extended maturation following plating, iCell neurons demonstrate functional synaptic vesicle recycling indicating the development of a presynaptic compartment. Synaptic vesicle recycling was monitored through FM1 -43 vesicle staining followed by Ca 2 7K + dependent depolarization ( Figures 22A-22D). The synaptic vesicles of BoNT intoxicated neurons can be stained, however Ca 2 7K + depolarization does not induce vesicle exocytosis and subsequent turn-off of FM1 -43 fluorescence.
  • this divalent inhibitory ligand is the most potent in vitro and in cell inhibitor of BoNT/A yet reported and represents the first use of a peripheral binding site to enhance the binding avidity and facilitate BoNTiA holotoxin binding.
  • This basic approach may have general applicability for developing high affinity and high specificity ligands that are designed to alter the function of inter-and intracellular targets.
  • hexafluorophosphate and PEG 4 (Fmoc-NH-PEG4-CH2CH2COOH, Fmoc-18-amino- 4,7,10,13, 16-pentaoxaoctadecanoic acid) were purchased from ChemPep.
  • DIEA diisoproylethylamine
  • TES triethylsilane
  • TFA Trifluoroacetic acid
  • TentaGel beads were purchased as 90 ⁇ S-NH2 beads, 0.29mmol/g, 2.86x1 06 beads/g from Rapp Polymere (Germany), Rink Amide resin was purchased from Anaspec and C-terminal biotinylated peptides were synthesized on Biotin NovaTag resin (EMD Millipore).
  • Cyclic peptide libraries were synthesized on a Titan 357 split-and-mix automated peptide synthesizer (Aapptec) via standard FMOC SPPS coupling chemistry using 90 ⁇ TentaGel S-NH 2 beads. All cyclic libraries included a C- terminal Lys(N3) residue, 18 L-stereoisomers of the natural amino acids, minus Cysteine and Methionine, at each of five randomized positions followed by a
  • Peptides were cleaved from the beads with deprotected side-chains using a 95:5:5 ratio of TFA: H20: TES.
  • the peptides were purified on a prep-scale Dionex U3000 HPLC with a reverse-phase C18 column (Phenomenex). All peptides are checked for correct mass and impurities using MALDI-TOF MS and are lyophilized to a powder for long-term storage at room temperature. Concentrated peptide stocks for assays are made by dissolving powder in small amounts of DMSO and measuring the A280 absorbance via Nanodrop to determine the stock concentration.
  • the peptidomimetic inhibitor Dab(Dinitrophenol)-RWT-Dab-ML as reported by Zuniga et al., (201 1 ) was scaled up as outlined above with a C-terminal PEG 4 biotin and an N-terminal PEG4 biotin.
  • the N-terminally labeled variant showed no detectable binding in a point ELISA format or inhibition in an in vitro BoNT LC activity assay, this is consistent with the crystal structure indicating a partially buried N- terminus when bound.
  • the C-terminally labeled variant was used as a control during the screening of various cyclic variants (Figure 17). Sixteen variants were
  • Peptide ligands were first immobilized onto Neutravidin ELISA plates (Pierce) for one hour at 1 ⁇ concentration.
  • a PEG 4 -biotin was used as the no-ligand blank, as the GST proteins has significant background binding to a blank Neutravidin plate.
  • the plates were then blocked with 5% BSA overnight. Protein was incubated at a concentration of 100nM for samples wells and the blank wells. GST protein alone (Abeam) was also incubated with the ligands and blanks as a control. The proteins were incubated for three hours at room temperature, then washed three times with 1 xTBS + 0.05% Tween-20.
  • the protein was then detected with 1 :1 0,000 anti-GST mouse mAb (Fisher) for one hour, washed three times with 1 xTBS + 0.05% Tween- 20 and developed with a 1 :1 mixture of TMB substrate for ten minutes. The samples were plotted by subtracting the blanks and averaging the sample wells, when included error bars indicate one standard deviation above and below.
  • FRET-based BoNT-LC activity assays were carried out as suggested by the manufacturer of the FRET pair labeled BoNT substrate (List Labs, SNAPtide #523). All time-resolved fluorescence assays were performed in a Flexstation3 fluorescent plate reader at 37 degrees. Briefly, 8 ⁇ of FRET-labeled substrate was prepared in Assay Buffer (50 mM HEPES, pH 7.4, containing 0.3 mM ZnCI2, 1 .25 mM DTT and 0.05% Tween-20) in a black fluorescence 96-well plate.
  • Assay Buffer 50 mM HEPES, pH 7.4, containing 0.3 mM ZnCI2, 1 .25 mM DTT and 0.05% Tween-20
  • BoNT LC-GST conjugate was diluted to the indicated concentration (generally 1 nM unless noted otherwise) and preincubated either with the indicated concentration of inhibitory peptide ligand, or a 0.05% DMSO control.
  • the plate reader adds the BoNT-LC to the substrate, and begins monitoring the fluorescence.
  • the excitation wavelength was set to 490 nm, and the emission to 523 nm with a cutoff at 495 nm. Wells were monitored for approximately one hour. Initial velocities of cleavage were plotted against inhibitor concentration.
  • lnh-1 and L2 were synthesized with fluorescein for fluorescence polarization (FP) assays.
  • the BoNT LC binding assays were completed by making a 1 ⁇ starting protein concentration and diluting 3x in Assay Buffer down a series of 10 wells in a black 96 well polystyrene plate. Ligand was added to the wells for a final concentration of 20nM. The plate was incubated at room temperature for one hour with shaking, and read on a Flexstation3 plate reader.
  • Step 1 Scrambled Epitope Preclear
  • Swelled library beads were blocked overnight in blocking buffer then washed with 1 x TBS three times.
  • the scrambled epitope (Lys(N3)-NGTLFNLSEVRH-PEG 4 - Biotin) Figure 1 5) was added at a concentration of 5 ⁇ in Blocking Buffer and incubated shaking at room temperature for four hours. The beads were washed three times with Blocking Buffer. 1 :10 000 Mouse mAb anti-Biotin alkaline
  • phosphatase conjugate (Abeam) was added in Blocking Buffer for one hour, followed by three washes in Blocking Buffer, three washes 1 x TBS + 0.05% Tween-20, and three 15 minute washes with a high-salt TBS buffer (1 x TBS with 750mM NaCI), then let shake in high salt buffer for one hour.
  • the beads were quenched with concentrated HCI to 0.1 N and washed with MilliQ water ten times to remove substrate. Beads were placed in a plate in 0.05N HCI. The purple beads (typically approximately 1 -5%) were removed by micropipette and discarded. The remaining beads were incubated in NMP 4 hours to remove trace purple precipitate from the BCIP/NBT reaction, then were washed five times with methanol, five times with water, five times with 1 xTBS and reblocked overnight in Blocking Buffer.
  • Step 2 Target Epitope Product Screen
  • Beads remaining from the preclear were washed three times with Blocking Buffer, then incubated with 5 ⁇ of the target epitope (Lys(N3)-SFGHEVLNLTRN, Figure 14) in Blocking Buffer for 12 hours to allow for an in situ click reaction to occur.
  • This screen was performed using a library with the form Pra-XXXXX-Pra- NYRWL-Lys(N3)-TG, with the azido and propargyl amino acids closest to the bead clicked together to form a closed cycle.
  • the peptide library was comprehensive from length zero to length five containing only four possible residues (Glycine, D-Leucine, Aminoisobutyrate and D-Proline, see Figure 2).
  • the N-terminus contained an alkyne amino acid for in situ click with the lnh-1— Biotin— Lys(N3) anchor inhibitor ( Figure 17).
  • Step 1 lnh-1 Interaction Preclear
  • Step 2 Target-guided Synthesis Product Screen
  • Beads remaining from the preclear were washed three times with Blocking Buffer, then incubated with 10 ⁇ of the anchor inhibitor (lnh-1— Biotin— Lys(N3)) Figure 17) and 10OnM BoNT LC in Blocking Buffer for either 2 or 12 hours to allow for an in situ click reaction to occur.
  • iCell Neuron Culture The cryopreserved hiPSC-derived neurons (iCell Neurons) were supplied by Cellular Dynamics International. The neurons were an— 98% pure (Tuj1 +/Nestin-) pan-neuronal population of GABAergic, glutamatergic, and a very small percentage ( ⁇ 1 %) of dopaminergic neurons. Neurons were thawed according to the provided instructions, and live cells were counted by the Trypan Blue exclusion method.
  • Cells were seeded at a density of 50,000 cells per well into Poly-D-Lysine Coated 96 Well plates (Corning) and 8.3 ⁇ g/cm 2 human Laminin (Sigma) unless otherwise indicated and incubated in neuronal medium with supplement as provided by Cellular
  • SNAP-25 was probed using Ms anti-SNAP-25 SMI-81 (Abeam) as a primary and goat anti-Ms H&L Alexafluor 790 (Life Technologies) as a secondary and imaged using an Odyssey instrument at the 800 nm wavelength.
  • Beta Tubulin was probed using Rb anti-beta Tubulin (Life Technologies) as a primary and goat anti-Rb H&L Alexafluor 680 (Life Technologies) as a secondary and imaged using an Odyssey instrument at the 700 nm wavelength.
  • Cleaved SNAP-25 bands appeared below the intact SNAP-25 band, and each were quantified by densitometry in ImageJ and the relative fraction of intact SNAP-25 indicated in Figures 4A-4B and 5A-3C.
  • neurons were cultured and exposed to toxin as indicated above. At the indicated times, 10 ⁇ - of neuronal medium spiked with inhibitory compounds were added at an appropriate concentration to bring the total concentration in the well to 1 ⁇ in a total volume of 60 ⁇ _. As above, 24 hours post exposure all cells were lysed with 1 x LDS and analyzed by western blot.
  • hiPSC-derived neurons were cultured as indicated above and allowed to mature, with 50% replacement of neuronal medium every three days. After 1 5 days, the neurons showed synaptic vesicle staining and destaining using FM1 -43 dye followed by K7Ca 2+ depolarization. These matured neuron cultures were exposed to the indicated BoNT/A holotoxin pre-incubated with inhibitor as indicated, and were then assayed with FM1 -43.
  • the lnh-1 peptide is coupled as detailed previously resulting in the compound NH 2 -Dab(DNP)-R-Lys(N3)-T-Dab(Boc)-Pra-L- Lys(MTT or Biotin) - T z 4-G-Aib-l-[Pra-NYRWL-Lys(N3)] where square brackets indicate a closed cycle.
  • This compound is then cyclized and chelated again as detailed above to create the bicyclic compound.
  • the MTT protecting group is removed from the Lys(MTT) by 10 washes with 1 % TFA in DCM. The protection group removal was monitored by the yellow color of the eluent.
  • DBCO-acid (Sigma) was coupled to the free amine, and STP (see synthesis above) was coupled with 1 .1 eq. using strain-promoted click chemistry in DMF overnight. This peptide is cleaved as normal with 95:5:5 TFA:H2O:TES and purified by reverse phase HPLC. The structure and MALDI-TOF spectrum of these compounds can be found in Figures 10, 18 and 20.

Abstract

The present application provides stable peptide-based Botulinum neurotoxin (BoNT) serotype A capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing BoNT serotype A capture agents using iterative on-bead in situ click chemistry.

Description

BOTULINUM NEUROTOXIN-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
RELATED APPLICATIONS
[0001] This application claims priority from U .S. Provisional Patent Application No. 62/1 33,891 , filed on March 1 6, 201 5, which is incorporated herein by reference in its entirety.
BACKGROUND
[0002] Botulinum neurotoxin (BoNT) serotype A is the most lethal known toxin. BoNT is produced by some species of the bacterial genus Clostridium and is a chemodenervating zinc-dependent protease that prevents the Ca2+-triggered release of acetylcholine in neuromuscular junctions by cleaving one of the three SNARE proteins required for synaptic vesicle formation and release. BoNT/A intoxication proceeds with selective binding to neuronal receptors, cell entry through receptor-mediated endocytosis, endosome escape via pH-induced translocation, and finally, cleavage of its SNAP-25 substrate in the cytosol. BoNT/A is comprised of a receptor-binding heavy chain and disulf ide-linked catalytic light chain (LC). This disulfide bond must be intact for the toxin to poison neurons, but must be broken for the LC to act catalytically in the cytosol. A subdomain (the 'belt') structurally occludes the intact holotoxin active site so that drug-induced inhibition only occurs after belt release, which is promoted by the reduction of the disulfide link by the cytosolic environment. The rapid sequestration of BoNT toxins into motor neurons limits current antibody based therapies, while molecular inhibitors cannot access the occluded active site of circulating BoNT. BoNT is a potentially deadly bioweapon, but is also a therapeutic and cosmetic agent, with an accompanying risk of accidental overdosing. Potent and effective inhibitors are needed.
SUMMARY
[0003] The present disclosure relates to chemically synthesized capture agents (called protein-catalyzed capture agents, or PCC Agents) that are designed to bind botulinum neurotoxin (BoNT) serotype A, methods for making said capture agents, methods for using said capture agents to inhibit BoNT serotype A and treat or prevent botulism or botulin toxin poisoning.
[0004] In one aspect, provided herein is a stable, synthetic capture agent that specifically binds to BoNT serotype A, wherein the botulinum neurotoxin serotype A protein comprises a heavy chain and a light chain, wherein the light chain comprises an enzymatic active site, wherein the capture agent comprises an anchor ligand and a secondary ligand and wherein the ligands selectively bind BoNT serotype A.
[0005] In another aspect, provided herein is a composition comprising one or more synthetic capture agents of the invention that specifically binds BoNT serotype A.
[0006] In another aspect, provided herein is a method for detecting BoNT serotype A in a biological sample, comprising the step of treating the biological sample with one or more capture agents of the invention.
[0007] In another aspect, provided herein is method of inhibiting SNAP-25 cleavage mediated by botulinum neurotoxin serotype A protein in one or more neurons in a subject in need thereof, the method comprising administering to the neurons an effective amount of one or more capture agents of the invention.
[0008] In another aspect, provided herein is method treating botulism in a subject in need thereof, the method comprising administering a therapeutically effective amount of one or more capture agents of the invention.
Anchor Ligand
[0009] In one embodiment of the capture agent, the anchor ligand specifically binds to the enzymatic active site of BoNT serotype A. In another embodiment, the anchor ligand comprises a cyclic peptide of the formula of Dab(DNP)-R-Lys(N3)-T-Dab-Pra- L-NH-, wherein the N3 and Pra moieties together represent a Tz4 or a Tz5 linkage. In another embodiment, the anchor ligand comprises a molecule of formula lnh-1
Figure imgf000004_0001
[0010] wherein R1 is absent or is a linker to the secondary ligand.
Secondary Ligand
[0011] In one embodiment, the secondary ligand specifically binds to a site on the botulinum neurotoxin serotype A protein that is 3-10 angstroms away from the enzymatic active site of the botulinum neurotoxin serotype A protein. In another embodiment, the secondary ligand specifically binds the botulinum neurotoxin serotype A light chain. In another embodiment, the secondary ligand specifically binds an occluded conformation of the botulinum neurotoxin serotype A holotoxin. In another embodiment, the secondary ligand specifically binds residues 166-179 of the botulinum neurotoxin serotype A light chain. In another embodiment, the secondary ligand comprises a cyclic peptide of the formula of -Pra-NYRWL-Lys(N3), wherein the N3 and Pra moieties together represent a Tz4 or a Tz5 linkage. In another embodiment, the secondary ligand comprises a molecule of formula L2
Figure imgf000004_0002
[0012] wherein R2 is absent or is a linker to the anchor ligand.
[0013] In another embodiment, the secondary ligand is selected from an epitope made up of residues 1 66-1 79 of the BoNT light chain screened against a 1 .1 million element library of macrocyclic 5-mer peptides. In another embodiment, the library is anti-screened against a scrambled version of the same epitope.
Linkers
[0014] In one embodiment, the capture agents described herein comprise a linker. In certain embodiments, the linker is a tripeptide. For example, the linker can comprise the amino acid sequence of Gly-Aib-Leu or Leu-Aib-Gly. In other embodiments, the linker comprises PEG4.
[0015] In certain embodiments, the anchor ligand and/or the secondary ligand are linked to the linker via a 1 ,4-substituted-1 ,2,3-triazole residue (Tz4) or via a 1 ,5-substituted-1 ,2,3-triazole residue (Tz5). In other embodiments, the anchor ligand is linked to the linker via a Tz4.
[0016] In certain embodiments, the linker is 3-1 0 angstroms in length. In other embodiments, the linker is 5-8 angstroms in length. In other embodiments, the linker has a length between 1 00 and 1 1 0% percent of the distance between the anchor ligand and the secondary ligand.
Triazole Linkage
[0017] In one embodiment of the capture agent, the anchor ligand and secondary ligand are linked together via a 1 ,4-substituted-1 ,2,3-triazole residue (Tz4). In another embodiment, the secondary ligand and the tertiary ligand are linked together via a 1 ,4-substituted-1 ,2,3-triazole residue (Tz4). In yet another embodiment, the tertiary ligand and the quarternary ligand are linked together via a 1 ,4-substituted-1 ,2,3-triazole residue (Tz4). In yet another embodiment, the anchor ligand and secondary ligand are linked together via a 1 ,4-substituted- 1 ,2,3-triazole residue, and the secondary ligand and the tertiary ligand are linked together via a 1 ,4-substituted-1 ,2,3-triazole residue. In yet another embodiment, the anchor ligand and secondary ligand are linked together via a 1 ,4-substituted-1 ,2,3-triazole residue, the secondary ligand and the tertiary ligand are linked together via a 1 ,4-substituted-1 ,2,3-triazole residue and the tertiary ligand and the quaternary ligand are linked together via a 1 ,4- substituted-1 ,2,3-triazole residue.
Biligands
[0018] In one embodiment, a capture agent of the invention is a biligand, comprising an anchor ligand and a secondary ligand. Non-limiting examples of secondary ligands are also disclosed in Figure 16.
[0019] In certain embodiments, the capture agent comprises a molecule of formula
!nh-2
Figure imgf000006_0001
wherein R3 is hydrogen, a capping group (e.g., an amide), or comprises a label or a spontaneously translocating peptide.
Properties
[0020] In certain embodiments, the BoNT serotype A capture agents provided herein are stable across a wide range of temperatures, pH's, storage times, storage conditions, and reaction conditions, and in certain embodiments the capture agents are more stable than a comparable antibody or biologic. In certain embodiments, the capture agents are stable in storage as a lyophilized powder. In certain embodiment, the capture agents are stable in storage at a temperature of about -80QC to about 60QC. In certain embodiments, the capture agents are stable at room temperature. In certain embodiments, the capture agents are stable in human serum for at least 24 hours. In certain embodiments, the capture agents are stable at a pH in the range of about 3 to about 1 2. In certain embodiments, the capture agents are stable as a powder for two months at a temperature of about 60QC.
Detectable Labels
[0021] In some embodiments, the capture agent is labeled with a label selected from the group consisting of biotin, copper-DOTA, biotin-PEG3,
aminooxyacetate, 19FB, 18FB, FITC-PEG3, fluorescein and fluorescein
derivatives (e.g. , 5-carboxy fluorescein). In other embodiments, the capture agent is labeled with the detectable moiety consisting of 64Cu DOTA, 68Ga DOTA, 18F, 64Cu, 68Ga, 89Zr, 124l, 86Y, 94mTc, 1 10m ln, 1 1C and 76Br. In other embodiments, the label is a fluorescent label. In a particular embodiment, the detectable label is 18F.
Translocating Peptides
[0022] In some embodiments, the capture agent comprises a translocating peptide. These translocating peptides allow the capture agents to enter eukaryotic cells. In certain embodiments, these eukaryotic cells are mammalian cells. In specific embodiments, these mammalian cells are human cells. In certain embodiments, the translocating peptide is a spontaneously translocating peptide. Optionally, the spontaneously translocating peptide comprises the amino acid sequence of pliylrllrGqf.
[0023] Other translocating peptides that can be used include H IV-TAT, penetratin, SynB1 , SynB2, PTD-4, PTD-5, FHV Coar (35-49), BMV Gag (7-25), HTLV- I I Rex (4-1 6), D-Tat, R9-Tat, transportan, MAP, SBP, FBP, MPG, Pep-1 , Pep-2, polyarginines, or polylysines. Any sequence at least 90% identical to any of the translocating peptides or fragments thereof may be used. Methods and Uses
[0024] Provided herein is a method of inhibiting SNAP-25 cleavage mediated by botulinum neurotoxin serotype A protein in one or more neurons in a subject in need thereof comprising administering to the neurons an effective amount of the capture agent as provided herein. In certain embodiments, inhibition of BoNT serotype A activity results in treatment or prevention of botulinism or botulin toxin poisoning.
Synthesis of Capture Agents
[0025] Provided herein are methods for making (i.e., synthesizing) the BoNT serotype A capture agents of the invention. In one embodiment, the method comprises the steps of:
a. identifying an anchor ligand and a secondary ligand that bind to the same target peptide at distinct epitopes;
b. identifying the binding sites of the anchor ligand and the secondary
ligand on the target peptide;
c. calculating the distance between the binding site of the anchor ligand and the secondary ligand; and
d. selecting a linker to connect the anchor ligand to the secondary ligand, thereby generating a capture agent, wherein the dissociation constant of the capture agent for binding to the target protein is lower than the dissociation constant of either the anchor ligand or the secondary ligand for binding to the target protein.
[0026] In one embodiment, the method further comprises the step of:
e. synthesizing the capture agent comprising the anchor ligand and secondary ligand of step (a) and the linker of step (d).
[0027] In one embodiment, the linking of the anchor ligand and the secondary ligand is performed using a linker. In certain embodiments, the linker has a length that is between 1 00 and 1 1 0% percent of the distance between the anchor ligand and the secondary ligand when both ligands are bound to the botulinum neurotoxin serotype A protein. [0028] Also provided herein are methods for making (i.e. , synthesizing) the BoNT serotype A capture agents of the invention. In one embodiment, the method comprises the steps of:
a. selecting an anchor ligand that specifically binds to the enzymatic active site of the botulinum neurotoxin serotype A protein;
b. selecting a secondary ligand that specifically binds at a distinct epitope from the anchor ligand within 5-1 0 angstroms on the botulinum neurotoxin serotype A protein; and
c. linking the anchor ligand and secondary ligand together,
wherein, the secondary ligand must bind to an epitope so that it specifically binds to an occluded conformation of the botulinum neurotoxin serotype A holotoxin, thereby synthesizing the capture agent for inhibiting SNAP-25 cleavage mediated by botulinum neurotoxin serotype A protein in one or more neurons.
BRIEF DESCRIPTION OF DRAWINGS
[0029] Figure 1 : The development of a biligand inhibitor of BoNT/A. lnh-1 (orange, Dab(DNP)-R-Lys(N3)-T-Dab-Pra-L-R1 ) is based on the natural peptide substrate for BoNT LC and previous structural studies of peptidomimetic substrate mimics. Epitope targeting was used to screen for a secondary ligand targeted to a nearby unstructured epitope (BoNT LC 166-1 79, green) exposed in the presence of the holotoxin's occluding belt (red). The ligand selected (L2, red, R2-Pra-NYRWL- Lys(N3)) was selected from a 1 100000 member macrocyclic peptide library.
[0030] Figure 2: Linker screen for divalent ligand development, lnh-1 was synthesized with a C-terminal azide and a biotin tag for readout of the in situ click screen and used in solution whereas L2 was synthesized with an N-terminal alkyne and a comprehensive linker library of oligopeptides of one to five units on Tentagel resin. An in situ protein-catalyzed click screen was performed to select for a minimally perturbative correctly oriented linker and resulted in hit sequences Gly- Aib- Leu and Leu-Aib-Gly. A PEG4 linker was also used in preliminary assays as a comparison (See Figures 18 and 1 9). lnh-2 was the biligand chosen for all future assays.
[0031] Figures 3A-3D: Characterization of ligand binding and inhibition in vitro. Figure 3A) Inhibition curve (left axis) and fluorescence polarization binding curve (right axis) of lnh-1 . An IC50 value of inhibition of 70±10 nM and a kp value of 68 ± 29 nM were obtained by Hill curve fitting. Figure 3B) Inhibition curve (left axis) and fluorescence polarization binding curve (right axis) of compound L2. No inhibition was observed, and a kp value of 78±8 nM was determined. Figure 3C) Inhibition curves comparing lnh-1 (pink) to lnh-2 (red). IC50 values of 60±1 1 nM and 165±15 pM, respectively, were observed. Figure 3D) Single-point ELISA binding data of compounds to the reduced (available active site) and intact (occluded by belt) BoNT/A holotoxins. Error bars indicate standard deviation of replicates.
[0032] Figures 4A and 4B: Ligand inhibition effect in a hiPSC-derived neuron system with BoNT holotoxin. Figure 4A) Top shows western blots of neuron lysates for B-tubulin (control) and SNAP (cleaved and uncleaved). The cleaved SNAP product appears as a longer running band below the intact SNAP in the western blot. Assays were performed with various concentrations of compounds Inh- 1 and lnh-2 along with a known endocytosis-inhibiting polyclonal sheep anti-BoNT heavy-chain antibody. The plot below shows the percentage of intact SNAP as a function of ligand concentration. This percentage was calculated as the ratio of the integrated intact band intensity to the total integrated intensity of the bands. Figure 4B) Top shows representative epifluorescence images of live neurons after FM1 -43 synaptic vesicle stain loading and after depolarization with and without prior BoNT intoxication; scale bars: 40 μιη. The plot below shows the average integrated synaptic vesicle stain intensity on a per-cell basis for all conditions with 1 μΜ added compound where relevant. Error bars indicate standard deviation of replicates.
[0033] Figures 5A-5C: Rescuing hiPSC- derived neurons from BoNT intoxication. Figure 5A) Experimental timeline of 55 U bolus toxin exposure (i) and 24 our incubation with 2 U toxin (ii). The protection effect was evaluated by preincubation of the toxin with 1 μιη inhibiting anti-BoNT pAb or lnh-2-STP, and the rescue effect was evaluated 1 , 3, and 12 hours after exposure to toxin by lysing cells and quantitating SNAP cleavage by western blot analysis and densitometry. In all cases, the cells were lysed 24 hours after toxin exposure. Figure 5B) Representative western blots of neuron lysates for B-tubulin (control) and SNAP (cleaved and uncleaved) after the rescue experiments shown in Figure 5A. The cleaved SNAP product appears as a longer running band below the intact SNAP in the western blot. Figure 5C) Percentage of intact SNAP as a function of exposure time before treatment. The percentage was calculated as the ratio of the integrated intact band intensity to the total integrated intensity of the bands. Error bars indicate standard deviation of replicates.
[0034] Figure 6: Click cyclized BoNT LC inhibitor (lnh-1) (Biotinylated). Sequence Dab(DNP)-R-[Lys(N3)-T-Dab-Pra]-L-PEG4-Biotin where square brackets indicate a closed cycle. Expected m/z 1 518.77, observed m/z 1518.61 .
[0035] Figure 7: Click cyclized BoNT LC inhibitor (lnh-1) (Fluorescein).
Sequence Dab(DNP)-R-[Lys(N3)-T-Dab-Pra]-L-Lys(PEG5-Biotin) where square brackets indicate a closed cycle. Expected m/z 1 779.82, observed m/z 1780.1 1 .
[0036] Figure 8: L-2 cyclic secondary binder (Biotinylated). Sequence Biotin- PEG5-[Pra-NYRWL-Lys(N3)] where square brackets indicate a closed cycle. Expected m/z 1516.75, observed m/z 151 6.35.
[0037] Figure 9: L-2 cyclic secondary binder (Fluorescein). Sequence Fluorescein-PEG5-Pra-NYRWL-Lys(N3) where square brackets indicate a closed cycle. Expected m/z 1648.72, observed m/z 1 648.89.
[0038] Figure 10: Divalent Inhibitor with in situ selected G-Aib-I linker (lnh-2).
Sequence NH2- Dab(DNP)-R-[Lys(N3)-T-Dab-Pra]-L-Lys(Biotin)-Tz4-G-Aib-l-[Pra- NYRWL-Lys(N3)] where square brackets indicate a closed cycle. Expected m/z 2848.44, observed m/z 2851 .23.
[0039] Figure 11 : Literature 310 helical BoNT LC inhibitor (biotinylated).
Sequence Dab(DNP)-RWT-Dab-ML-PEG4-Biotin. Expected m/z 1 586.81 , observed m/z 1 586.16.
[0040] Figure 12: Preliminary ELISA curves of inhibitory ligands. Candidate substrate mimic ligand BoNT LC binding was evaluated by sandwich ELISA and compared to the literature inhibitor (blue).
[0041] Figures 13A-13C: Representative in vitro BoNT LC activity assays.
Typical time-fluorescence traces showing cleavage of SNAP-25 FRET substrate with various concentrations of BoNT LC, with the initial 2000 seconds zoomed in and fit to a Vmax initial slope to gather kinetics data. Vmax observed as a function of BoNT LC concentration shown. [0042] Figure 14: MALDI-TOF spectrum of biotinylated BoNT LC fragment.
Amino acids 1 66-179 of BoNT LC. Sequence Lys(N3)-SFGHEVLNLTRN-PEG4- Biotin. Expected m/z 2099.09, observed m/z 2099.45.
[0043] Figure 15: MALDI-TOF spectrum of biotinylated scrambled fragment. Sequence Lys(N3)-NGTLFNLSELRH-PEG4-Biotin. Expected m/z 2099.09, observed m/z 2098.06.
[0044] Figure16: List of hit sequences of epitope targeted screen. Beads were sequenced by Edman degredation and colors indicate similar sidechain residues to better illustrate homology, dashes indicate amino acids involved in the click cycle.
[0045] Figure 17: Click cyclized BoNT LC inhibitor (lnh-1) for target-guided screen. Sequence Dab(DNP)-R-[Lys(N3)-T-Dab-Pra]-L-Lys(Biotin)-Lys(N3). Expected m/z 1510.77, observed m/z 151 0.90.
[0046] Figure 18: Divalent Inhibitor (lnh-2) with PEG4 linker. Sequence NH2- Dab(DNP)-R-[Lys(N3)-T-Dab-Pra]-L-Lys(Biotin) - Tz4-PEG4-[Pra-NYRWL-Lys(N3)]. Expected m/z 2801 .38, observed m/z 2799.45.
[0047] Figure 19: Single point sandwich ELISA comparing BoNT ligand variants. Peptides were immobilized on neutravidin resin at 1 μΜ concentration and blocked in 3% BSA for 3 hours. Bound ligands were incubated with 50 nM BoNT LC- GST conjugate or buffer blank for three hours. ELISAs were probed with anti-GST- HRP mAb as detailed in protocols and developed.
[0048] Figure 20: Divalent Inhibitor with g-Aib-l linker and STP (lnh-2-STP).
Sequence NH2-Dab(DNP)-R-[Lys(N3)-T-Dab-Pra]-L-Lys(DBCO-STP) - Tz4-G-Aib-I- [Pra-NYRWL-Lys(N3)], where STP is D-peptide Lys(N3)-pliyirlirGqf. Expected m/z 4533.21 , observed m/z 4536.45.
[0049] Figure 21 : Neurite outgrowth in iCell Neurons. Neurons 4 days after plating were stained according to the manufacturer's instructions with Neurite Outgrowth and Viability stains (Life Technologies), consisting of a Calcein viability stain (green) and a Dil C18 membrane stain (blue). All cells show a morphology consistent with neuronal outgrowth.
[0050] Figures 22A-22D: Synaptic vesicle recycling in iCell Neurons. FM1 -43 stain (yellow) and nuclear stains (red) on live neurons after 15 days post-plating. Figure 22A) FM1 -43 labeled control cells, no depolarization Figure 22B) FM1 -43 labeled BoNT intoxicated cells, after depolarization, Figure 22C) FM1 -43 labeled control cells, after depolarization, Figure 22D) Unlabeled BoNT intoxicated cells. All labeling and depolarization is described in the SI procedures.
[0051] Figure 23: Image analysis of synaptic vesicle intensity. Images were analyzed by ImageJ. A watershed analysis was used to find the edges of neuron cell bodies in the transmission channel and allocate a given intercellular area to each cell. These areas were then mapped onto the FM1 -43 layer and puncta were counted in each area using the PunctaAnalyzer package while ignoring the previously identified cell bodies to find only synaptic vesicle puncta along neurites. The puncta count for each cell was averaged over two wells with two fields of view per well.
[0052] Figure 24: Evaluation of cytosolic delivery of STP with polar cargo.
Sequence of peptide is Cy5-DBCO-Lys(N3)-pliylrllrGqf. Cells were treated at 1 μΜ concentration for 30 minutes. After incubation the cells were washed once with neuronal medium and 2x with HBSS. One final wash was given with the suggested dilution of NucBlue Live Readyprobe (Life Technologies) in order to visualize the cell nuclei.
DETAILED DESCRIPTION
[0053] Provided herein is a capture agent that specifically binds botulinum neurotoxin serotype A and inhibits its ability to cleave SNAP-25 in neurons. In one embodiment, the capture agent comprises at least two ligands. One of the two ligands specifically binds to the enzymatic active site located on the light chain of botulinum neurotoxin serotype A and the other ligand binds at distinct location on the botulinum neurotoxin serotype A protein. According to certain embodiments, the second binding site is within 3-1 0 angstroms from the first binding site. According to other embodiments, the ligand that binds to the second binding site is able to specifically bind the occluded conformation of the botulinum neurotoxin serotype A holotoxin. According to other embodiments, the second binding site is also on the light chain of botulinum neurotoxin serotype A.
[0054] According to certain embodiments, an anchor ligand is chosen that binds to the enzyme active site of botulinum neurotoxin serotype A protein. This enzyme active site is located on the light chain of the protein. According to certain embodiments, the anchor ligand inhibits the activity of the enzyme active site of botulinum neurotoxin serotype A protein. According to some embodiments, the anchor protein inhibits the activity of botulinum neurotoxin serotype A protein at an inhibition constant of between 1 0 and 1 000 nM. According to other embodiments, the inhibition constant is between 1 0 and 200 nM. According to other embodiments, the inhibition constant is between 30 and 1 00 nM, 50 and 80 nM or 65 and 75 nM. According to certain embodiments, the inhibition constant is about 70 nM.
[0055] According to certain embodiments, a secondary ligand is chosen that also binds to the botulinum neurotoxin serotype A protein. In certain embodiments, the secondary ligand is able to bind the occluded conformation of the botulinum neurotoxin serotype A holotoxin. In certain embodiments, the secondary ligand binds to an epitope close enough to the binding site of the anchor ligand that a linker can be provided to connect the two ligands. In certain embodiments, the secondary ligand is chosen as a result of screening a combinatorial library.
[0056] According to certain embodiments, a linker is chosen that connects the two ligands. In certain embodiments, the linker is rigid and similar in length to the distance between at least one portion of the two ligands when they are bound to the botulinum neurotoxin serotype A protein. In certain embodiments, the portions of the ligands are the N- or C- termini. In one embodiment, the linker is about the length equal to the root mean square average separation of the two binding sites. In certain embodiments, the linker is chosen as a result of screening a combinatorial linker library.
[0057] The following description of the invention is merely intended to illustrate various embodiments of the invention. As such, the specific modifications discussed are not to be construed as limitations on the scope of the invention. It will be apparent to one skilled in the art that various equivalents, changes, and modifications may be made without departing from the scope of the invention, and it is understood that such equivalent embodiments are to be included herein.
[0058] Unless the context requires otherwise, throughout the present
specification and claims, the word "comprise" and variations thereof, such as, "comprises" and "comprising" are to be construed in an open, inclusive sense, that is as "including, but not limited to".
[0059] Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment.
Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
Definitions
[0060] As used herein, the terms "capture agent of the invention", and "capture agents of the invention" refer to synthetic protein-catalyzed capture agents which bind botulinum neurotoxin serotype A, as described herein.
[0061] "Amino" refers to the -N H2 radical.
[0062] "Cyano" refers to the -CN radical.
[0063] "Hydroxy" or "hydroxyl" refers to the -OH radical.
[0064] "Imino" refers to the =N H substituent.
[0065] "Nitro" refers to the -NO2 radical.
[0066] "Oxo" refers to the =O substituent.
[0067] "Thioxo" refers to the =S substituent.
[0068] "Alkyi" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, which is saturated or unsaturated {i.e., contains one or more double and/or triple bonds), having from one to twelve carbon atoms (C1 -C12 alkyi), preferably one to eight carbon atoms (d-Cs alkyi) or one to six carbon atoms (C1 -C6 alkyi), and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl,
1 -methylethyl (/'so- propyl), /7-butyl, /7-pentyl, 1 , 1 -dimethylethyl (f-butyl),
3-methylhexyl, 2-methylhexyl, ethenyl, prop-1 -enyl, but-1 -enyl, pent-1 -enyl, penta-1 ,4-dienyl, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. Unless stated otherwise specifically in the specification, an alkyl group may be optionally substituted.
[0069] "Alkylene" or "alkylene chain" refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, which is saturated or unsaturated {i.e., contains one or more double and/or triple bonds), and having from one to twelve carbon atoms, e.g., methylene, ethylene, propylene, n-butylene, ethenylene, propenylene, n-butenylene, propynylene, n-butynylene, and the like. The alkylene chain is attached to the rest of the molecule through a single or double bond and to the radical group through a single or double bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain may be optionally substituted.
[0070] "Alkoxy" refers to a radical of the formula -ORa where Ra is an alkyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted.
[0071] "Aminocarbonyl" refers to a radical of the formula -C(=0) NRaRa, where each Ra is independently H, alkyl or a linker moiety.
[0072] "oc-amino carbonyl" refers to a radical of the formula - C(=0)CRb(NRaRa)-, where each Ra is independently H, alkyl or a linker moiety and Rb is H or alkyl. In some embodiments, an alpha amino carbonyl is part of a cyclic moiety (e.g., peptide) where the carbonyl is within the ring and the amino (NRaRa) is exocyclic. For example, in certain embodiments and alpha aminocarbonyl is useful for Edman degradation of cyclic peptides.
[0073] "oc-amido carbonyl" refers to a radical of the formula - C(=0)CRb(N(C=0) RaRa)-, where each Ra is independently H, alkyl or a linker moiety and Rb is H or alkyl. In some embodiments, an alpha amido carbonyl is part of a cyclic moiety (e.g., peptide) where the carbonyl is within the ring and the amido (N(C=0)RaRa) is exocyclic. [0074] "Alkylamino" refers to a radical of the formula -NH Ra or -NRaRa where each Ra is, independently, an alkyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkylamino group may be optionally substituted.
[0075] "Thioalkyl" refers to a radical of the formula -SRa where Ra is an alkyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, a thioalkyl group may be optionally substituted.
[0076] "Aryl" refers to a hydrocarbon ring system radical comprising hydrogen, 6 to 1 8 carbon atoms and at least one aromatic ring. For purposes of this invention, the aryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems. Aryl radicals include, but are not limited to, aryl radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless stated otherwise specifically in the specification, the term "aryl" or the prefix "ar-" (such as in "aralkyl") is meant to include aryl radicals that are optionally substituted.
[0077] "Aralkyl" refers to a radical of the formula -Rb-Rc where Rb is an alkylene chain as defined above and Rc is one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl and the like. Unless stated otherwise
specifically in the specification, an aralkyl group may be optionally substituted.
[0078] "Cycloalkyl" or "carbocyclic ring" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from three to fifteen carbon atoms, preferably having from three to ten carbon atoms, and which is saturated or unsaturated and attached to the rest of the molecule by a single bond. Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic radicals include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1 ]heptanyl, and the like. Unless otherwise stated specifically in the specification, a
cycloalkyl group may be optionally substituted. [0079] "Cycloalkylalkyl" refers to a radical of the formula -Rb d where Rb is an alkylene chain as defined above and Rd is a cycloalkyi radical as defined above. Unless stated otherwise specifically in the specification, a cycloalkylalkyl group may be optionally substituted.
[0080] "Fused" refers to any ring structure described herein which is fused to an existing ring structure in the compounds of the invention. When the fused ring is a heterocyclyl ring or a heteroaryl ring, any carbon atom on the existing ring structure which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring may be replaced with a nitrogen atom.
[0081] "Halo" or "halogen" refers to bromo, chloro, fluoro or iodo.
[0082] "Haloalkyl" refers to an alkyl radical, as defined above, that is
substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1 ,2-difluoroethyl,
3-bromo-2-fluoropropyl, 1 ,2-dibromoethyl, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group may be optionally substituted.
[0083] "Heterocyclyl" or "heterocyclic ring" refers to a stable 3- to 1 8-membered non-aromatic ring radical which consists of two to twelve carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. Unless stated otherwise specifically in the specification, the heterocyclyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be partially or fully saturated. Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1 ,3]dithianyl, decahydroisoquinolyl, imidazolinyl , imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl , pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl,
tetrahydropyranyl , thiomorpholinyl, thiamorpholinyl, 1 -oxo-thiomorpholinyl, and 1 , 1 -dioxo-thiomorpholinyl. Unless stated otherwise specifically in the
specification, a heterocyclyl group may be optionally substituted. [0084] "/V-heterocyclyl" refers to a heterocyclyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a nitrogen atom in the heterocyclyl radical. Unless stated otherwise specifically in the specification, a /V-heterocyclyl group may be optionally substituted.
[0085] "Heterocyclylalkyl" refers to a radical of the formula -RbRe where Rb is an alkylene chain as defined above and Re is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the
heterocyclyl may be attached to the alkyl radical at the nitrogen atom. Unless stated otherwise specifically in the specification, a heterocyclylalkyl group may be optionally substituted.
[0086] "Heteroaryl" refers to a 5- to 1 4-membered ring system radical
comprising hydrogen atoms, one to thirteen carbon atoms, one to six
heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and at least one aromatic ring. For purposes of this invention, the heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized ; the nitrogen atom may be optionally quaternized. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl,
benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl,
benzo[b][1 ,4]dioxepinyl, 1 ,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl,
benzo[4,6]imidazo[1 ,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1 -oxidopyridinyl, 1 -oxidopyrimidinyl, 1 -oxidopyrazinyl, 1 -oxidopyridazinyl, 1 -phenyl-1 H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e. thienyl). Unless stated otherwise specifically in the specification, a heteroaryl group may be optionally substituted.
[0087] "N-heteroaryl" refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical. Unless stated otherwise specifically in the specification, an N-heteroaryl group may be optionally substituted.
[0088] "Heteroarylalkyl" refers to a radical of the formula -RbRf where Rb is an alkylene chain as defined above and Rf is a heteroaryl radical as defined above. Unless stated otherwise specifically in the specification, a heteroarylalkyl group may be optionally substituted.
[0089] The term "substituted" used herein means any of the above groups (e.g., alkyl, alkylene, alkoxy, alkylamino, aminocarbonyl, oc-aminocarbonyl, oc- amidocarbonyl , thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, /V-heterocyclyl, heterocyclylalkyl, heteroaryl, /V-heteroaryl and/or heteroarylalkyl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, CI, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines,
alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl groups; and other heteroatoms in various other groups.
"Substituted" also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple- bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles. For example, "substituted" includes any of the above groups in which one or more hydrogen atoms are replaced
with -N RgRh, -NRgC(=0)Rh, -NRgC(=0)NRgRh, -NRgC(=0)ORh, -NRgS02Rh, -OC
(=0) NRgRh, -ORg, -SRg, -SORg, -S02Rg, -OS02Rg, -S02ORg, =NS02Rg, and -S02NRgRh. "Substituted" also means any of the above groups in which one or more hydrogen atoms are replaced with C(=0)Rg, C(=0)ORg, C(=0) NRgRh, CH2S02Rg, CH2S02NRgRh. ln the foregoing, Rg and Rh are the same or different and independently hydrogen, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl , heterocyclyl, /V-heterocyclyl,
heterocyclylalkyl, heteroaryl, /V-heteroaryl and/or heteroarylalkyl . "Substituted" further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, /V-heterocyclyl, heterocyclylalkyl, heteroaryl, N- heteroaryl and/or heteroarylalkyl group. In addition, each of the foregoing substituents may also be optionally substituted with one or more of the above substituents.
[0090] "Prodrug" is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound of the invention. Thus, the term "prodrug" refers to a metabolic precursor of a
compound of the invention that is pharmaceutically acceptable. A prodrug may be inactive when administered to a subject in need thereof, but is converted in vivo to an active compound of the invention. Prodrugs are typically rapidly transformed in vivo to yield the parent compound of the invention, for example, by hydrolysis in blood. The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, Bundgard, H., Design of Prodrugs (1 985), pp. 7-9, 21 -24 (Elsevier, Amsterdam)). A discussion of prodrugs is provided in Higuchi, T., et al., A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, Ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1 987.
[0091] The term "prodrug" is also meant to include any covalently bonded carriers, which release the active compound of the invention in vivo when such prodrug is administered to a mammalian subject. Prodrugs of a compound of the invention may be prepared by modifying functional groups present in the compound of the invention in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound of the invention. Prodrugs include compounds of the invention wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the compound of the invention is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol or amide derivatives of amine functional groups in the compounds of the invention and the like.
[0092] The invention disclosed herein is also meant to encompass all pharmaceutically acceptable peptides of structure (I) or ( Γ) being isotopically- labelled by having one or more atoms replaced by an atom having a different atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2H, 3H, 1 1C, 13C, 14C, 13N, 15N, 150, 170, 180, 31 P, 32P, 35S, 18F, 36CI, 123l, and 125l, respectively. These radiolabeled compounds could be useful to help determine or measure the effectiveness of the compounds, by characterizing, for example, the site or mode of action, or binding affinity to pharmacologically important site of action. Certain isotopically-labelled peptides of the invention, for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e. 3H , and carbon-14, i.e. 14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
[0093] Substitution with heavier isotopes such as deuterium, i.e. 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
[0094] Substitution with positron emitting isotopes, such as 1 1C, 18F, 150 and 13N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled peptides can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Preparations and Examples as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
[0095] The invention disclosed herein is also meant to encompass the in vivo metabolic products of the disclosed peptides. Such products may result from, for example, the oxidation, reduction, hydrolysis, amidation, esterification, and the like of the administered compound, primarily due to enzymatic processes.
Accordingly, the invention includes compounds produced by a process comprising administering a compound of this invention to a mammal for a period of time sufficient to yield a metabolic product thereof. Such products are typically identified by administering a radiolabelled compound of the invention in a detectable dose to an animal, such as rat, mouse, guinea pig, monkey, or to human, allowing sufficient time for metabolism to occur, and isolating its conversion products from the urine, blood or other biological samples.
[0096] "Mammal" includes humans and both domestic animals such as laboratory animals and household pets (e.g., cats, dogs, swine, cattle, sheep, goats, horses, rabbits), and non-domestic animals such as wildlife and the like.
[0097] "Mutant" or "Variant" refers to a protein that has high homology to a wild-type amino acid sequence, but not 1 00% identity with the wild-type amino acid sequence. High homology associated with mutants or variants is higher than 95, 96, 97, 98 or 99% but less than 1 00%. In certain embodiments, a mutant or variant differs from a wild-type sequence at 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 1 0 amino acids.
[0098] In certain embodiments, the sequence of BoNT serotype A refers to the amino acid sequence shown below.
1 rapvt innfny ndpidnnni i mmeppfargt gryykafkit dr iwiipery tfgykpedfn
61 kssgifnrdv ceyydpdyln tndkkniflq tmiklfnrik skplgeklle miingipylg
121 drrvpleefn tniasvtvnk lisnpgever kkgifanlii fgpgpvlnen etidigiqnh
181 fasregfggi mqmkfcpeyv svfnnvqenk gasifnrrgy fsdpalilmh elihvlhgly
241 gikvddlp iv pnekkffmqs tdaiqaeely tfggqdpsii tpstdksiyd kvlqnfrgiv
301 drlnkvlvci sdpnininiy knkfkdkykf vedsegkys i dvesfdklyk slmfgftetn
361 iaenykiktr asyfsdslpp vkiknlldne iytieegfni sdkdmekeyr gqnkainkqa
421 yeei skehla vykiqmcksv kapgicidvd nedlffiadk ns fsddl skn erieyntkni
481 yienyfsine lildtdlisg ielpsentes ltdfnvdvpv yekqpaikki ftdentifqy
541 lysqtfpldi rdisltssfd dal Ifsnkvy sffsmdyikt ankvveaglf agwvkqi idd
601 fvieanks st mdkiadi si i vpyiglalnv gnetakgnfe nafeiagasi liefipelli
661 pvvgaflies yidnknkiik tidnaltkrv ekwidmygl i vaqwlstvnt qfytikegmy 721 kalnyqaqal eeiikykyni ysekeklnin idfndinskl neginqaidn innfinecsv
781 sylmkkmipl aieklldfdn alkknllnyi denklyligs veeekskvdk ffktiipfdl
841 smytnnti li emvnkynsei lnniilnlry rdnnlidssg ygakvevyng velndknqfk
901 ltssanskik vtqnqnitfn smfldfsvsf wiripkyknd giqnyihney tiincmknns
961 gwki sirgnr i iwt ltding ktksvffeys iredi sdyin rwff titnn ldnakiying
1021 klesnidird irevivnge i ifkldgeidr tqfiwmkyfs ifntel sqsn vke iykiqsy
1081 skylkdfwgn plmynkeyym fnagnknsyi klvkdssvge iltrskynqn snyinyrnly
1141 igekfiirrk sssqsisddi vrkedyiyld ffnsnrewrv yayknfkgqe eklflaniyd
1201 snefyktiqi keydeqptys cql Ifkkdee stdeigligi hnfyesgilf kdykdyfcis
1261 kwylkevkkk pyssnlgcnw qfipkdegwt e
[0099] The above sequence is the full sequence of the holoenzyme. This holoenzyme is cleaved into light chain and heavy chain peptides. In certain embodiments, the light chain is made up of amino acids 1 -448 above and the heavy chain is made of of amino acids 449-1 291 .
[00100] "Optional" or "optionally" means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, "optionally substituted aryl" means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.
[00101] "Pharmaceutically acceptable carrier, diluent or excipient" includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
[00102] "Pharmaceutically acceptable salt" includes both acid and base addition salts.
[00103] "Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4- acetamidobenzoic acid, camphoric acid, camphor-1 0-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1 ,2-disulfonic acid, ethanesulfonic acid, 2- hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1 ,5- disulfonic acid, naphthalene-2-sulfonic acid, 1 -hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p- toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like.
[00104] "Pharmaceutically acceptable base addition salt" refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, /V-ethylpiperidine, polyamine resins and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, tri methylamine, dicyclohexylamine, choline and caffeine.
[00105] The compounds (peptides) of the invention, or their pharmaceutically acceptable salts may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined , in terms of absolute stereochemistry, as (R)- or ( S)- or, as (D)- or (L)- for amino acids. The present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-) , (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography ( H PLC) . When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included. (D)-amino acids (also referred to as D-amino acids) are referred to herein in lower case letters (e.g. D-valine is referred to as "v") , while (L)-amino acids (also referred to herein as L-amino acids) are referred to in upper case letters (e.g. L-valine or valine is referred to as "V") . Glycine is non-chiral and is referred to as "G".
[00106] A "stereoisomer" refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present invention contemplates various stereoisomers and mixtures thereof and includes "enantiomers", which refers to two stereoisomers whose molecules are nonsuperimposeable mirror images of one another.
[00107] A "tautomer" refers to a proton shift from one atom of a molecule to another atom of the same molecule. The present invention includes tautomers of any said compounds. [00108] Often crystallizations produce a solvate of the compound of the invention. As used herein, the term "solvate" refers to an aggregate that comprises one or more molecules of a compound of the invention with one or more molecules of solvent. The solvent may be water, in which case the solvate may be a hydrate. Alternatively, the solvent may be an organic solvent. Thus, the compounds of the present invention may exist as a hydrate, including a monohydrate, dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate and the like, as well as the corresponding solvated forms. The compound of the invention may be true solvates, while in other cases, the compound of the invention may merely retain adventitious water or be a mixture of water plus some adventitious solvent.
[00109] The term "capture agent" as used herein refers to a composition that comprises one or more target-binding moieties and which specifically binds to a target protein via those target-binding moieties. Each target-binding moiety exhibits binding affinity for the target protein, either individually or in
combination with other target-binding moieties. In certain embodiments, each target-binding moiety binds to the target protein via one or more non-covalent interactions, including for example hydrogen bonds, hydrophobic interactions, and van der Waals interactions. A capture agent may comprise one or more organic molecules, including for example polypeptides, peptides,
polynucleotides, and other non-polymeric molecules. In some aspects a capture agent is a protein catalyzed capture agent (PCC).
[00110] The term "epitope" as used herein refers to a distinct molecular surface of a protein (e.g., the BoNT serotype A protein). Typically, the epitope is a polypeptide and it can act on its own as a finite sequence of 1 0-40 amino acids. In the present disclosure, at least two epitopes are bound. The first epitope involves the enzymatic active site of the epitope BoNT serotype A. In certain embodiments, the anchor ligand binds this enzymatic active site with high affinity so that its activity is inhibited. In certain embodiments, the second epitope is a portion of the BoNT serotype A holotoxin that is solvent exposed in the occluded conformation. For example, this epitoipe can be amino acids 1 66- 1 79 of the BoNT serotype A (light chain). [00111] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to an amino acid sequence comprising a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residues is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers.
[00112] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids, and isomers thereof. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline,
carboxyglutamate, O-phosphoserine, and isomers thereof. The term "amino acid analogs" refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. The term "amino acid mimetics" refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid. Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the lU PAC- IU B Biochemical Nomenclature Commission.
[00113] The term "non-natural amino acid" as used herein refers to an amino acid that is different from the twenty naturally occurring amino acids (alanine, arginine, glycine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, serine, threonine, histidine, lysine, methionine, proline, valine, isoleucine, leucine, tyrosine, tryptophan, phenylalanine) in its side chain functionality. The non-natural amino acid can be a close analog of one of the twenty natural amino acids, or it can introduce a completely new functionality and chemistry, as long as the hydrophobicity of the non-natural amino acid is either equivalent to or greater than that of the natural amino acid. The non-natural amino acid can either replace an existing amino acid in a protein (substitution), or be an addition to the wild type sequence (insertion). The incorporation of non-natural amino acids can be accomplished by known chemical methods including solid-phase peptide synthesis or native chemical ligation, or by biological methods. Non- natural amino acids can include 2-aminoisobutyric acid (Aib) and
propargylglycine (Pra).
[00114] The terms "specific binding," "selective binding," "selectively binds," or "specifically binds" as used herein refer to capture agent binding to an epitope on a predetermined antigen. Typically, the capture agent binds with an affinity (KD) of approximately less than 1 0"5 M, such as approximately less than 1 0"6 M, 1 0"7 M, 1 0"8 M, 1 0"9 M or 1 0"1 0 M or even lower.
[00115] The term "KD" as used herein refers to the dissociation equilibrium constant of a particular capture agent-antigen interaction. Typically, the capture agents of the invention bind to BoNT serotype A protein with a dissociation equilibrium constant (KD) of less than approximately 1 0"6 M, 1 0"7 M, 1 0"8 M, 1 0"9 M or 1 0"1 0 M or even lower, for example, as determined using surface plasmon resonance (SPR) technology in a Biacore instrument using the capture agent as the ligand and the BoNT serotype A protein as the analyte, and bind to a BoNT serotype A protein with an affinity corresponding to a KD that is at least ten-fold lower, such as at least 1 00 fold lower, for instance at least 1 000 fold lower, such as at least 1 0,000 fold lower, for instance at least 1 00,000 fold lower than its affinity for binding to a non-specific antigen (e.g., BSA, casein) other than the predetermined antigen or a closely-related antigen. The amount with which the affinity is lower is dependent on the KD of the capture agent, so that when the KD of the capture agent is very low (that is, the capture agent is highly specific), then the amount with which the affinity for the antigen is lower than the affinity for a non-specific antigen may be at least 1 0,000 fold.
[00116] The term "kd" (sec-1) as used herein refers to the dissociation rate constant of a particular capture agent-antigen interaction. Said value is also referred to as the k0ff value.
[00117] The term "ka" (M~1 xsec~1) as used herein refers to the association rate constant of a particular capture agent-antigen interaction. [00118] The term "KD" (M) as used herein refers to the dissociation equilibrium constant of a particular capture agent-antigen interaction.
[00119] The term "KA" (M~1) as used herein refers to the association equilibrium constant of a particular capture agent-antigen interaction and is obtained by dividing the ka by the kd.
[00120] A "pharmaceutical composition" refers to a formulation of a compound of the invention and a medium generally accepted in the art for the delivery of the biologically active compound to mammals, e.g., humans. Such a medium includes all pharmaceutically acceptable carriers, diluents or excipients therefor.
[00121] The term "condition" as used herein refers generally to a disease, event, or a change in health status. A change in health status may be associated with a particular disease or event, in which case the change may occur simultaneously with or in advance of the disease or event. In those cases where the change in health status occurs in advance of a disease or event, the change in health status may serve as a predictor of the disease or event. For example, a change in health status may be an alteration in the expression level of a particular gene associated with a disease or event. Alternatively, a change in health status may not be associated with a particular disease or event. In specific embodiments, the condition is botulism or botulin toxin poisoning.
[00122] The terms "treat," "treating," or "treatment" as used herein generally refer to preventing a condition or event, slowing the onset or rate of
development of a condition or delaying the occurrence of an event, reducing the risk of developing a condition or experiencing an event, preventing or delaying the development of symptoms associated with a condition or event, reducing or ending symptoms associated with a condition or event, generating a complete or partial regression of a condition, lessening the severity of a condition or event, or some combination thereof.
[00123] An "effective amount" or "therapeutically effective amount" as used herein refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result. A therapeutically effective amount of a capture agent may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the capture agent to elicit a desired response in the individual.
[00124] The term "antibody" as used herein refers to a protein of the kind that is produced by activated B cells after stimulation by an antigen and can bind specifically to the antigen promoting an immune response in biological systems. Full antibodies typically consist of four subunits including two heavy chains and two light chains. The term antibody includes natural and synthetic antibodies, including but not limited to monoclonal antibodies, polyclonal antibodies or fragments thereof. Exemplary antibodies include IgA, IgD, IgGI, lgG2, lgG3, Ig M and the like. Exemplary fragments include Fab, Fv, Fab', F(ab')2 and the like. A monoclonal antibody is an antibody that specifically binds to and is thereby defined as complementary to a single particular spatial and polar organization of another biomolecule which is termed an "epitope." In some forms, monoclonal antibodies can also have the same structure. A polyclonal antibody refers to a mixture of different monoclonal antibodies. In some forms, polyclonal antibodies can be a mixture of monoclonal antibodies where at least two of the monoclonal antibodies binding to a different antigenic epitope. The different antigenic epitopes can be on the same target, different targets, or a combination.
Antibodies can be prepared by techniques that are well known in the art, such as immunization of a host and collection of sera (polyclonal) or by preparing continuous hybridoma cell lines and collecting the secreted protein (monoclonal).
[00125] The term "stable" as used herein with regard to a capture agent protein catalyzed capture agent or pharmaceutical formulation thereof refers to the agent or formulation retaining structural and functional integrity for a sufficient period of time to be utilized in the methods described herein.
[00126] The term "synthetic" as used herein with regard to a protein catalyzed capture agent or capture agent refers to the capture agent has been generated by chemical rather than biological means.
[00127] Unless otherwise stated, sequence identity/similarity values provided herein refer to the value obtained using the BLAST 2.0 suite of programs using default parameters (Altschul, et al., (1 997) Nucleic Acids Res. 25:3389-402). [00128] As those of ordinary skill in the art will understand, BLAST searches assume that proteins can be modeled as random sequences. However, many real proteins comprise regions of nonrandom sequences, which may be homopolymeric tracts, short-period repeats, or regions enriched in one or more amino acids. Such low-complexity regions may be aligned between unrelated proteins even though other regions of the protein are entirely dissimilar. A number of low-complexity filter programs can be employed to reduce such low- complexity alignments. For example, the SEG (Wooten and Federhen, (1 993) Comput. Chem. 1 7:149-63) and XN U (Claverie and States, (1 993) Comput. Chem. 1 7: 1 91 -201 ) low-complexity filters can be employed alone or in combination.
[00129] As used herein, "sequence identity" or "identity" in the context of two nucleic acid or polypeptide sequences includes reference to the residues in the two sequences, which are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. Where sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences, which differ by such conservative substitutions, are said to have "sequence similarity" or "similarity." Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non- conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1 . The scoring of conservative substitutions is calculated, e.g., according to the algorithm of Meyers and Miller, (1 988)
Computer Applic. Biol. Sci. 4:1 1 -1 7, e.g., as implemented in the program
PC/GEN E ( Intelligenetics, Mountain View, Calif. , USA). [00130] As used herein, "percentage of sequence identity" means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 1 00 to yield the percentage of sequence identity.
[00131] The term "substantial identity" or "substantially identical" of
polynucleotide sequences means that a polynucleotide comprises a sequence that has between 50-1 00% sequence identity, preferably at least 50% sequence identity, preferably at least 60% sequence identity, preferably at least 70%, more preferably at least 80%, more preferably at least 90% and most preferably at least 95%, compared to a reference sequence using one of the alignment programs described using standard parameters. One of skill will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like.
Substantial identity of amino acid sequences for these purposes normally means sequence identity of between 55-1 00%, preferably at least 55%, preferably at least 60%, more preferably at least 70%, 80%, 90% and most preferably at least 95%.
[00132] As used herein in the context of cyclic peptides, it will be understood that N3 and Pra moieties together represent a Tz4 or a Tz5 linkage.
Development of BoNT Serotype A capture agents
[00133] Antibodies are currently the default detection agent for use in diagnostic platforms. However, antibodies possess several disadvantages, including high cost, poor stability, and, in many cases, lack of proper characterization and high specificity. The ideal replacement for use in diagnostic assays should be synthetic, stable to a range of thermal and chemical conditions, and display high affinity and specificity for the target of interest.
[00134] A high quality monoclonal antibody possesses low-nanomolar affinity and high target specificity. Interestingly, structural and genetic analyses of the antigen recognition surface have shown that the majority of the molecular diversity of the variable loops is contained in a single highly variable loop (CDR- H3). In humans, this loop ranges in size from 1 -35 residues (1 5 on average), can adopt a wide range of structural conformations, and is responsible for most of the interactions with the antigen. The other five loops are significantly less diverse and adopt only a handful of conformations. This suggests that a carefully selected "anchor" peptide can dominate the mode and strength of the interaction between a capture agent and its target protein. It also suggests that other peptide components, while providing only modest contributions to the total interaction energy, can supply important scaffolding features and specificity elements.
[00135] In situ click chemistry is a technique in which a small molecule enzymatic inhibitor is separated into two moieties, each of which is then expanded into a small library - one containing acetylene functionalities, and the other containing azide groups. The enzyme itself then assembles the 'best fit' inhibitor from these library components by selectively promoting 1 ,3-dipolar cycloaddition between the acetylene and azide groups to form a triazole linkage (the 'click' reaction). The protein effectively plays the role of an extremely selective variant of the Cu(l) catalyst that is commonly used for such couplings. The enzyme promotes the click reaction only between those library components that bind to the protein in the right orientation. The resultant inhibitor can exhibit far superior affinity characteristics relative to the initial inhibitor that formed the basis of the two libraries.
[00136] Sequential in situ click chemistry extends the in situ click chemistry concept to enable the discovery of multiligand capture agents (see: USSN 201 00009896, incorporated herein by reference). This process was used previously to produce a triligand capture agent against the model protein carbonic anhydrase I I (CAM) . Sequential in situ click chemistry has several advantages. First, structural information about the protein target is replaced by the ability to sample a very large chemical space to identify the ligand components of the capture agent. For example, an initial ligand may be identified by screening the protein against a large (> 1 06 element) one-bead- one-compound (OBOC) peptide library, where the peptides themselves may be comprised of natural, non-natural, and/or artificial amino acids. The resultant anchor ligand is then utilized in an in situ click screen, again using a large OBOC library, to identify a biligand binder. A second advantage is that the process can be repeated, so that the biligand is used as an anchor to identify a triligand, and so forth. The final capture agent can then be scaled up using relatively simple and largely automated chemistries, and it can be developed with a label, such as a biotin group, as an intrinsic part of its structure. This approach permits the exploration of branched, cyclic, and linear capture agent architectures. While many strategies for protein-directed multiligand assembly have been described, most require detailed structural information on the target to guide the screening strategy, and most (such as the original in situ click approach), are optimized for low-diversity small molecule libraries.
[00137] The present embodiment further generalizes the in situ click application to find a linker that links two ligands to a single protein. This method uses cooperative binding to make a capture ligand with higher affinity than either of its component ligands.
BoNT Serotype A capture agents
[00138] In one aspect, provided herein is a stable, synthetic capture agent that specifically binds BoNT Serotype A, wherein the capture agent comprises a designed anchor ligand, a designed secondary ligand, optionally a designed tertiary ligand, and optionally a designed quarternary ligand, and wherein the ligands selectively bind BoNT Serotype A. In one embodiment, the capture agent specifically binds the enzymatic active site of BoNT Serotype A. In another embodiment, the capture agent specifically binds a site of BoNT Serotype A that is accessible on the occluded conformation of the holotoxin.
[00139] In certain embodiments, provided herein are biligand BoNT Serotype A capture agents comprising two target-binding moieties. The first target-binding moiety is referred to as an anchor ligand, and the second is referred to as a secondary ligand. Also provided are triligand and tetraligand capture agents, wherein the third target-binding moiety is referred to as a tertiary ligand, and the fourth target- binding moiety is referred to as a quarternary ligand.
[00140] In certain embodiments, a target-binding moiety comprises one or more polypeptides or peptides. In certain of these embodiments, a target-binding moiety comprises one or more peptides comprising D-amino acids, L-amino acids, and/or amino acids substituted with functional groups selected from the group consisting of substituted and unsubstituted alkyl, substituted and unsubstituted azido, substituted and unsubstituted alkynyl, substituted and unsubstituted biotinyl, substituted and unsubstituted azioalkyl, substituted and unsubstituted polyethyleneglycolyl, and substituted and unsubstituted 1 ,2,3-triazole.
[00141] In certain embodiments, the anchor ligand and secondary ligand are linked to one another via a covalent linkage to form a capture agent biligand. In certain of these embodiments, the anchor ligand and secondary ligand are linked to one another via an amide bond or a 1 ,4-disubstituted-1 ,2,3-triazole linkage as shown below:
Figure imgf000036_0001
1 ,4-disubstituted-1 ,2,3-triazole linkage.
[00142] In those embodiments where the anchor and secondary ligands are linked to one another via a 1 ,4-disubstituted-1 ,2,3-triazole linkage, the 1 ,4-disubstituted - 1 ,2,3-triazole linkage may be formed by Cu-Catalyzed Azide/Alkyne Cycloaddition (CuAAC).
[00143] In certain embodiments, the anchor and secondary ligands are linked to one another by a Tz4 linkage having the following structure:
Figure imgf000037_0001
[00144] In certain embodiments, the anchor and secondary ligands are linked to one another by a Tz5 linkage having the following structure:
Figure imgf000037_0002
[00145] In certain embodiments, the tertiary and/or quarternary ligand is linked to the capture agent biligand by a covalent linkage, preferably via the secondary ligand in the biligand. In certain of these embodiments, the tertiary ligand and the biligand and/or the quarternary ligand and the tertiary ligand are linked to one another by a Tz4 linkage.
[00146] In those embodiments wherein one or more of the anchor, secondary, tertiary, and/or quarternary ligands are linked to one another via amide bonds, the amide bond may be formed by coupling a carboxylic acid group and an amine group in the presence of a coupling agent (e.g., 0-(7-azabenzotriazol-1 -yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate (HATU), N-hydroxy-7-aza-benzotriazole (HOAt), or diisopropylethylamine (DIEA) in DMF).
[00147] In certain embodiments, the capture agents provided herein are stable across a range of reaction conditions and/or storage times. A capture agent that is "stable" as used herein maintains the ability to specifically bind to a target protein. In certain embodiments, the capture agents provided herein are more stable than an antibody binding to the same target protein under one or more reaction and/or storage conditions. For example, in certain embodiments the capture agents provided herein are more resistant to proteolytic degradation than an antibody binding to the same target protein.
[00148] In certain embodiments, the capture agents provided herein have a shelf-life of greater than six months, meaning that they are stable in storage for greater than six months. In certain of these embodiments, the capture agents have a shelf-life of one year or greater, two years or greater, or more than three years. In certain of these embodiments, the capture agents are stored as a lyophilized powder. In certain embodiments, the capture agents provided herein have a longer shelf-life than an antibody binding to the same target protein.
[00149] In certain embodiments, the capture agents provided herein are stable at temperatures ranging from about -80° to about 1 20°C. In certain of these
embodiments, the capture agents are stable within a temperature range of -80° to - 40 °C; -40° to -20 °C; -20° to 0°C; 0° to 20 °C; 20° to 40 °C; 40° to 60 °C; 60° to 80 °C; and/or 80° to 120°C. In certain embodiments, the capture agents provided herein are stable across a wider range of temperatures than an antibody binding to the same target protein, and/or remain stable at a specific temperature for a longer time period than an antibody binding to the same target protein.
[00150] In certain embodiments, the capture agents provided herein are stable at a pH range from about 3.0 to about 8.0. In certain embodiments, the range is about 4.0 to about 7.0. In certain embodiments, the range is about 7.0 to about 8.0.
[00151] In certain embodiments, the capture agents provided herein are stable in human serum for more than 1 2 hours. In certain of these embodiments, the capture agents are stable in human serum for more than 18 hours, more than 24 hours, more than 36 hours, or more than 48 hours. In certain embodiments, the capture agents provided herein are stable for a longer period of time in human serum than an antibody binding to the same target protein. In certain embodiments, the capture agents are stable as a powder for two months at a temperature of about 60 QC.
[00152] In certain embodiments, the capture agents provided herein may comprise one or more detection labels, including for example biotin, copper-1 ,4,7,10- tetraazacyclododecane-1 ,4,7, 10-tetraacetic acid (copper- DOTA), 64Cu DOTA, 68Ga DOTA, 18F, 64Cu, 68Ga, 89Zr, 124l, 86Y, 94mTc, 110mln, 11C, 76Br, 123l, 131 l, 67Ga, 1 11 ln and 99mTc, or other radiolabeled products that may include gamma emitters, proton emitters, positron emitters, tritium, or covered tags detectable by other methods (i.e., gadolinium) among others. In a particular embodiment, the detection label is 18F. In certain embodiments, the capture agents may be modified to be used as imaging agents. The imaging agents may be used as diagnostic agents.
[00153] In certain embodiments, the capture agents provided herein may be modified to obtain a desired chemical or biological activity. Examples of desired chemical or biological activities include, without limitation, improved solubility, stability, bioavailability, detectability, or reactivity. Examples of specific modifications that may be introduced to a capture agent include, but are not limited to, cyclizing the capture agent through formation of a disulfide bond; modifying the capture agent with other functional groups or molecules. Similarly, a capture agent may be synthesized to bind to non-canonical or non-biological epitopes on proteins, thereby increasing their versatility. In certain embodiments, the capture agent may be modified by modifying the synthesis blocks of the target-binding moieties before the coupling reaction.
Methods of making/screening capture agents
[00154] Provided herein in certain embodiments are methods of screening target- binding moieties and/or making capture agents that comprise these target-binding moieties. Methods for screening target-binding moieties and/or making capture agents that comprise these target-binding moieties can also be found in International Publication Nos. WO 2012/106671 , WO 2013/033561 , WO 2013/009869 and WO 2014/074907, each of which is incorporated by reference, herein, in their entireties.
[00155] The capture agent production methods disclosed herein begin with identification of a short-chain anchor peptide, then proceed by adding additional covalently coupled peptide ligands via a process that is promoted by the target protein. The specificity and inhibitory potency of the final multiligand capture agent are augmented by the peripheral peptide ligands.
In Vitro
[00156] For detection of BoNT Serotype A in solution, a capture agent of the invention can be detectably labeled, then contacted with the solution, and thereafter formation of a complex between the capture agent and the BoNT Serotype A target can be detected. As an example, a fluorescently labeled capture agent can be used for in vitro BoNT Serotype A detection assays, wherein the capture agent is added to a solution to be tested for BoNT Serotype A under conditions allowing binding to occur. The complex between the fluorescently labeled capture agent and the BoNT Serotype A target can be detected and quantified by, for example, measuring the increased fluorescence polarization arising from the complex-bound peptide relative to that of the free peptide.
[00157] Alternatively, a sandwich-type "ELISA" assay can be used, wherein a capture agent is immobilized on a solid support such as a plastic tube or well, then the solution suspected of containing BoNT Serotype A is contacted with the immobilized binding moiety, non-binding materials are washed away, and complexed polypeptide is detected using a suitable detection reagent for recognizing BoNT Serotype A.
[00158] For detection or purification of soluble BoNT Serotype A from a solution, capture agents of the invention can be immobilized on a solid substrate such as a chromatographic support or other matrix material, then the immobilized binder can be loaded or contacted with the solution under conditions suitable for formation of a capture agent/BoNT Serotype A complex. The non-binding portion of the solution can be removed and the complex can be detected, for example, using an anti-BoNT Serotype A antibody, or an anti-binding polypeptide antibody, or the BoNT Serotype A can be released from the binding moiety at appropriate elution conditions.
In Vivo Diagnostic Imaging
[00159] A particularly preferred use for the capture agents of the invention is for creating visually readable images of BoNT Serotype A or BoNT Serotype A- expressing cells in a biological fluid. The BoNT Serotype A capture agents disclosed herein can be converted to imaging reagents by conjugating the capture agents with a label appropriate for diagnostic detection. Preferably, a capture agent exhibiting much greater specificity for BoNT Serotype A than for other proteins is conjugated or linked to a label appropriate for the detection methodology to be employed. For example, the capture agent can be conjugated with or without a linker to a paramagnetic chelate suitable for Magnetic Resonance Imaging (MRI), with a radiolabel suitable for x-ray, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) or scintigraphic imaging (including a chelator for a radioactive metal), with an ultrasound contrast agent (e.g., a stabilized microbubble, a microballoon, a microsphere or what has been referred to as a gas filled "liposome") suitable for ultrasound detection, or with an optical imaging dye.
[00160] In another embodiment, rather than directly labeling a capture agent with a detectable label or radiotherapeutic construct, one or more peptides or constructs of the invention can be conjugated with for example, avidin, biotin, or an antibody or antibody fragment that will bind the detectable label or radiotherapeutic.
A. Magnetic Resonance Imaging
[00161] The BoNT Serotype A capture agents described herein can advantageously be conjugated with a paramagnetic metal chelate in order to form a contrast agent for use in MRI. Preferred paramagnetic metal ions have atomic numbers 21 -29, 42, 44, or 57-83. This includes ions of the transition metal or lanthanide series which have one, and more preferably five or more, unpaired electrons and a magnetic moment of at least 1 .7 Bohr magneton. Preferred paramagnetic metals include, but are not limited to, chromium (II I), manganese (II), manganese (III), iron (II), iron (I II), cobalt (II), nickel (II), copper (II), praseodymium (II I), neodymium (III), samarium (III), gadolinium (III), terbium (III), dysprosium (III), holmium (III), erbium (III), europium (III) and ytterbium (III), chromium (III), iron (III), and gadolinium (III). The trivalent cation, Gd3+, is particularly preferred for MRI contrast agents, due to its high relaxivity and low toxicity, with the further advantage that it exists in only one biologically
accessible oxidation state, which minimizes undesired metabolysis of the metal by a patient. Another useful metal is Cr3+, which is relatively inexpensive. Gd(ll l) chelates have been used for clinical and radiologic MR applications since 1988, and approximately 30% of MRI exams currently employ a gadolinium-based contrast agent.
[00162] The paramagnetic metal chelator is a molecule having one or more polar groups that act as a ligand for, and complex with, a paramagnetic metal. Suitable chelators are known in the art and include acids with methylene phosphonic acid groups, methylene carbohydroxamine acid groups, carboxyethylidene groups, or carboxymethylene groups. Examples of chelators include, but are not limited to, diethylenetriaminepentaacetic acid (DTPA), 1 ,4,7,10-tetraazacyclo-tetradecane- 1 ,4,7,1 0-tetraacetic acid (DOTA), 1 -substituted 1 ,4,7,-tricarboxymethyl-1 ,4,7,1 0- teraazacyclododecane (D03A), ethylenediaminetetraacetic acid (EDTA), and 1 ,4,8,1 1 -tetra-azacyclotetradecane-1 ,4,8,1 1 -tetraacetic acid (TETA). Additional chelating ligands are ethylene bis-(2-hydroxy-phenylglycine) (EHPG), and derivatives thereof, including 5-CI-EHPG, 5-Br-EHPG, 5-Me-EHPG, 5-t-Bu-EHPG, and 5-sec-Bu-EHPG; benzodiethylenetriamine pentaacetic acid (benzo-DTPA) and derivatives thereof, including dibenzo-DTPA, phenyl-DTPA, diphenyl-DTPA, benzyl- DTPA, and dibenzyl DTPA; bis-2 (hydroxybenzyl)-ethylene-diaminediacetic acid (HBED) and derivatives thereof; the class of macrocyclic compounds which contain at least 3 carbon atoms, more preferably at least 6, and at least two heteroatoms (O and/or N), which macrocyclic compounds can consist of one ring, or two or three rings joined together at the hetero ring elements, e.g., benzo-DOTA, dibenzo-DOTA, and benzo-NOTA, where NOTA is 1 ,4,7-triazacyclononane Ν,Ν',Ν''-triacetic acid, benzo-TETA, benzo-DOTMA, where DOTMA is 1 ,4,7, 10-tetraazacyclotetradecane- 1 ,4,7,1 0-tetra(methyl tetraacetic acid), and benzo-TETMA, where TETMA is
1 ,4,8,1 1 -tetraazacyclotetradecane-1 ,4,8,1 1 -(methyl tetraacetic acid); derivatives of 1 ,3-propylene-diaminetetraacetic acid (PDTA) and triethylenetetraaminehexaacetic acid (TTHA); derivatives of 1 ,5, 10?N,N',N"-tris(2,3-dihydroxybenzoyl)-tricatecholate (LICAM); and 1 ,3,5-N,N',N"-tris(2,3-dihydroxybenzoyl)aminomethylbenzene
(MECAM). A preferred chelator for use in the present invention is DTPA, and the use of D03A is particularly preferred. Examples of representative chelators and chelating groups contemplated by the present invention are described in WO 98/18496, WO 86/06605, WO 91 /03200, WO 95/28179, WO 96/23526, WO 97/36619,
PCT/US98/01473, PCT/US98/201 82, and U.S. Pat. No. 4,899,755, U.S. Pat. No. 5,474,756, U.S. Pat. No. 5,846,519 and U.S. Pat. No. 6,143,274, all of which are hereby incorporated by reference.
[00163] In accordance with the present invention, the chelator of the MRI contrast agent is coupled to the BoNT Serotype A capture agent. The positioning of the chelate should be selected so as not to interfere with the binding affinity or specificity of the BoNT Serotype A capture agent. The chelate also can be attached anywhere on the capture agent.
[00164] In general, the BoNT Serotype A capture agent can be bound directly or covalently to the metal chelator (or other detectable label), or it can be coupled or conjugated to the metal chelator using a linker, which can be, without limitation, amide, urea, acetal, ketal, double ester, carbonyl, carbamate, thiourea, sulfone, thioester, ester, ether, disulfide, lactone, imine, phosphoryl, or phosphodiester linkages; substituted or unsubstituted saturated or unsaturated alkyl chains; linear, branched, or cyclic amino acid chains of a single amino acid or different amino acids (e.g., extensions of the N- or C-terminus of the BoNT Serotype A binding moiety); derivatized or underivatized polyethylene glycols (PEGs), polyoxyethylene, or polyvinylpyridine chains; substituted or unsubstituted polyamide chains; derivatized or underivatized polyamine, polyester, polyethylenimine, polyacrylate, polyvinyl alcohol), polyglycerol, or oligosaccharide (e.g., dextran) chains; alternating block copolymers; malonic, succinic, glutaric, adipic and pimelic acids; caproic acid; simple diamines and dialcohols; any of the other linkers disclosed herein; or any other simple polymeric linkers known in the art (see, for example, WO 98/1 8497 and WO 98/18496). Preferably the molecular weight of the linker can be tightly controlled. The molecular weights can range in size from less than 100 to greater than 1000.
Preferably the molecular weight of the linker is less than 100. In addition, it can be desirable to utilize a linker that is biodegradable in vivo to provide efficient routes of excretion for the imaging reagents of the present invention. Depending on their location within the linker, such biodegradable functionalities can include ester, double ester, amide, phosphoester, ether, acetal, and ketal functionalities.
[00165] In general, known methods can be used to couple the metal chelate and the BoNT Serotype A capture agent using such linkers (WO 95/28967, WO 98/18496, WO 98/18497 and discussion therein). The BoNT Serotype A binding moiety can be linked through an N- or C-terminus via an amide bond, for example, to a metal coordinating backbone nitrogen of a metal chelate or to an acetate arm of the metal chelate itself. The present disclosure contemplates linking of the chelate on any position, provided the metal chelate retains the ability to bind the metal tightly in order to minimize toxicity.
[00166] MRI contrast reagents prepared according to the disclosures herein can be used in the same manner as conventional MRI contrast reagents. Certain MR techniques and pulse sequences can be preferred to enhance the contrast of the site to the background blood and tissues. These techniques include (but are not limited to), for example, black blood angiography sequences that seek to make blood dark, such as fast spin echo sequences (Alexander, A. et al., 1998. Magn. Reson. Med., 40: 298-31 0) and flow-spoiled gradient echo sequences (Edelman, R. et al., 1990. Radiology, 177: 45-50). These methods also include flow independent techniques that enhance the difference in contrast, such as inversion-recovery prepared or saturation-recovery prepared sequences that will increase the contrast between BoNT Serotype A positive tissue and negative tissues. Finally, magnetization transfer preparations also can improve contrast with these agents (Goodrich, K. et al., 1996. Invest. Radia, 31 : 323-32).
Therapeutic Applications
[00167] Provided herein in certain embodiments are methods of using the BoNT Serotype A capture agents disclosed herein to inhibit the activity of BoNT Serotype A in vitro or in vivo. The BoNT Serotype A capture agents disclosed herein can be used to treat botulinism or improve one or more symptoms associated with
botulinism.
[00168] In certain embodiments, the BoNT Serotype A capture agents disclosed herein are able to bind the occluded conformation of the BoNT Serotype A holotoxin. This occluded conformation is removed when BoNT Serotype A is translocated inside of a cell, for example a neuron. This allows access for inhibitors to the enzymatic active site of BoNT Serotype A. In certain embodiments, the BoNT
Serotype A capture agent binds to the protein before it is internalized into a cell, providing access for the active site binding portion of the capture agent when it is transferred into the cell along with the BoNT Serotype A protein.
[00169] The following examples are provided to better illustrate the claimed invention and are not to be interpreted as limiting the scope of the invention. To the extent that specific materials are mentioned, it is merely for purposes of illustration and is not intended to limit the invention. One skilled in the art may develop equivalent means or reactants without the exercise of inventive capacity and without departing from the scope of the invention.
EXAMPLES
[00170] Example 1 . Screening strategy for Botulinum Neurotoxin-specific liqand.
[00171] A macrocyclic peptide ligand was developed (lnh-1 , Figures 6 and 7) that is a substrate mimic for BoNT. lnh-1 binds to the active site with a approximatlely 70 nM binding affinity (kp) and similar inhibition constant. An all synthetic in situ click epitope targeting approach (shown in Figure 1 ) was employed to identify a second peptide macrocycle (L2, Figures 8 and 9) that binds to a site a few angstroms away in the folded protein structure from the active site. L2 exhibits a ko of approximately 80 nM, but no inhibitory effects. Finally, an in situ click screen was utilized, promoted by the BoNT LC, to identify a linear peptide that connects the two macrocycles
(shown in Figure 2). The final divalent ligand (lnh-2, Figure 1 0) inhibits the BoNT LC with an IC50 of 1 65 ± 15 pM. lnh-2 is also carried into neuronal cells by BoNT itself, and inhibits the holotoxin in live cells. This technique provides a potentially general route for the development of peripheral and active site binders from naive libraries for combination through in situ click target-guided synthesis.
[00172] The active site of the catalytic BoNT/A LC recognizes the 7-residue
QRATKML sequence of the SNAP-25 protein. Many inhibitors based on this motif have been reported. One peptidomimetic inhibitor variant resulting from a structure- based search binds BoNT in a tight 3io helical conformation with low nanomolar inhibition of BoNT LC in vitro (Figures 1 1 and 1 2). In an effort to reinforce this conformation in solution and increase chemical and biological stability of this compound, a small library of (i, i+3)-click cyclized derivatives was synthesized. One compound (lnh-1 ) inhibited BoNT/A LC with a 70 ± 8 nM inhibition constant measured in vitro using a FRET-based substrate cleavage assay (Figures 1 3A-13C) and 68 ± 29 nM binding affinity using fluorescence polariNation (Figure 3A).
However, inhibiting the full BoNT holotoxin with the occluded LC active site is more challenging. Single point ELISA binding data (Figure 3D) shows that the lnh-1 exhibits minimal binding to the holotoxin despite tight binding to the LC. Thus, lnh-1 was expanded to include a moiety that binds to a non-occluded region of BoNT LC adjacent to the active site. For this purpose, an epitope which is solvent exposed in the occluded conformation of the holotoxin was selected for screening with epitope- catalyed in situ click.
[00173] The epitope (BoNT LC residues 166-179, Figure 14) was synthesized with an N-terminal azidolysine and a C-terminal biotin and was screened against a 1 .1 M element library of macrocyclic 5-mer peptides synthesized on Tentagel resin substituted with an N-terminal propargylglycine (shown in Figure 2) and anti- screened against a scrambled version of the same epitope (Figure 15). This constrained macrocyclic peptide library was used due to the increased stability and decreased entropic penalty of binding relative to linear peptides. After incubation with the target epitope, beads were stripped, probed and developed with an alkaline phosphatase anti-biotin mAb. Nine hit beads were sequenced using Edman degradation and found to have significant sequence homology (Figure 1 6). L2 was selected after fluorescence polarization showed a 78 ± 13 nM binding affinity to both the BoNT LC and the BoNT holotoxin, but no measurable LC inhibition (Figure 3B).
[00174] To optimally combine lnh-1 with L2, kinetic in situ target-guided synthesis was used with a combinatorial linker library, (shown in Figure 2) to identify an optimized molecular bridge. To this end, L2 was synthesized on Tentagel resin and appended with an N-terminal linker library that was terminated with a
propargylglycine. This appended library was comprehensive from zero to five residues in four non-canonical and alternate chirality amino acids that were selected for structural rigidity. The rational for this library was to maximize the avidity enhancement that can be achieved when combining two independent binders. That enhancement is maximized with a rigid linker of length equal to the root mean square average separation of the two binding sites, lnh-1 was synthesized with a C-terminal azidolysine and a biotin assay handle (Figure 1 7). The BoNT LC was added to promote the target guided synthesis of a bivalent ligand by bringing the reactive azide and alkyne groups in close proximity. After screening, beads were stripped, probed and developed with an alkaline phosphatase anti-biotin mAb. Hit beads were sequenced using Edman degradation and resulted in a consensus of two linker sequences: Gly - Aib - Leu and Leu - Aib - Gly (shown in Figure 2). A control bivalent ligand was synthesized with a PEG4 linker of similar RMSD length to compare to the linkers selected through target-guided synthesis (Figures 18 and 19). Candidate bivalent ligands were scaled up and evaluated as inhibitors of BoNT LC in vitro as above, lnh-2 was selected for all subsequent assays and demonstrated an inhibition constant of 1 65 ± 15 pM against BoNT LC. Variants of this ligand were synthesized with a fluorescein dye for fluorescence polarization, a biotin for binding assays and a spontaneously translocating peptide (STP) reported for the delivery of polar cargo to the cytosol (Figure 20).
[00175] The ability of lnh-2 to protect and rescue BoNT intoxication in human neurons was tested (Figures 4A-4B and 5A-5C respectively). Used was a type of human induced pluripotent stem cell derived neurons known as iCell neurons, which have been reported as a sensitive model for monitoring SNAP-25 cleavage by BoNT in the complex environment of living cells (Figure 21 ). Cells were plated on poly-D- lysine coated 96-well plates with a laminin matrix and exposed to 2 mouse LD50 units (U) of BoNT pre-incubated with various concentrations of lnh-1 and lnh-2. All cells were lysed after 24 hours and evaluated for SNAP-25 cleavage by western blotting. Cleaved SNAP-25 appeared as a second band under the intact SNAP-25 band (Figure 4A). Western blotting data was quantified by densitometry to extract a dose- response behavior of the ligands in protection against BoNT intoxication, lnh-1 exhibited negligible protective effects at up to 1 0 μΜ dosing. This is likely due to the occluded active site being unavailable for binding until BoNT enters the cytosol, and the membrane impermeable nature of lnh-1 . lnh-2 is also impermeable to cell membranes, but demonstrated significant protective effect to BoNT intoxication at concentrations as low as 1 00 nM. This type of protection has been reported for inhibitors of the BoNT LC active site in neuron models, but only at inhibitor concentrations in the mid micromolar range. As a comparison, a polyclonal antibody acquired from the Army Critical Reagents program repository with known significant anti-toxin effect was evaluated. This antibody protects against BoNT intoxication by interrupting the heavy chain receptor-mediated endocytosis and provides significant protection into the low to mid nanomolar range.
[00176] After extended maturation following plating, iCell neurons demonstrate functional synaptic vesicle recycling indicating the development of a presynaptic compartment. Synaptic vesicle recycling was monitored through FM1 -43 vesicle staining followed by Ca27K+ dependent depolarization (Figures 22A-22D). The synaptic vesicles of BoNT intoxicated neurons can be stained, however Ca27K+ depolarization does not induce vesicle exocytosis and subsequent turn-off of FM1 -43 fluorescence. Synaptic vesicles appearing as puncta in epifluorescent images of the live neurons were quantified on a per cell basis (Figure 23) after exposure to BoNT pre-incubated with 1 μΜ of inhibitory ligands. Representative cells following depolarization are shown in Figure 4B along with the synaptic vesicle counts for each condition quantified over three wells. As observed in the western blot assay, this functional assay shows negligible protection to BoNT intoxication by lnh-1 , while lnh-2 provides full protection. These results are consistent with a Trojan horse-like inhibition mechanism in which the non-inhibiting L2 moiety of lnh-2 binds to the BoNT holotoxin, so that lnh-2 is shuttled into the cell by the holotoxin itself during the endocytosis step of BoNT intoxication. Once the belt is released, the lnh-1 moiety clamps down onto the active site, thus inhibiting the protein. To evaluate the effect of passive delivery to the cytosol, ligands were appended with an STP (Figure 24). The lnh-1 -STP compound targeting the active site showed increased protection
compared to the membrane impermeable lnh-1 , though not the complete protection expected at this concentration for the BoNT LC in vitro.
[00177] Both the membrane permeable and impermeable lnh-2 variants provided complete functional protection in neurons. Evaluated next was the BoNT- independent cellular entry of lnh-2-STP through rescue assays in which BoNT entry and intoxication begin before the addition of the inhibitor. Rescue was evaluated in iCell neurons in a bolus 55U five-minute exposure in cell-stimulating media followed by washing and an extended 1 U exposure with no washing. In both experiments 1 μΜ inhibitory ligand was added to the cells 1 , 3 and 12 hours post-exposure. All cells were lysed 24 hours after exposure and SNAP-25 cleavage was evaluated by western blotting (Figure 5B). Two blots per condition were quantified and averaged by densitometry (Fig. 3C). In the bolus exposure, lnh-2-STP exhibits partial rescue from internalized BoNT as late as 3 hours after exposure, with later time points indicating the internalized BoNT had completely cleaved SNAP-25 after 1 2 hours. As expected, the sheep pAb shows no detectable rescue due to its mechanism of action, which is to prevent BoNT endocytosis. In the 1 U extended exposure, both the sheep pAb and compound lnh-2-STP showed similar levels of rescue. The process of BoNT endocytosis is slowed significantly at low concentrations and in non- stimulating media, enabling protection through the pAb protective mechanism.
[00178] The rational use of the tertiary structure of a protein target was reported as a landscape for the assembly of a highly potent inhibitor. The specific application yielded a ligand, lnh-2 that succeeds as a strong inhibitor in spite of the naturally occluded active site of BoNT holotoxin. lnh-2 effectively acts as a Trojan horse; it is carried into the neuronal cells by the BoNT machinery. Once inside the cytosol, the BoNT LC active site is exposed and lnh-2 performs its inhibitory function. To our knowledge this divalent inhibitory ligand is the most potent in vitro and in cell inhibitor of BoNT/A yet reported and represents the first use of a peripheral binding site to enhance the binding avidity and facilitate BoNTiA holotoxin binding. This basic approach may have general applicability for developing high affinity and high specificity ligands that are designed to alter the function of inter-and intracellular targets.
[00179] Standard Materials
[00180] All amino acids were purchased from Aapptec as the Fmoc carboxylic acid with standard TFA side-chain protecting groups for solid phase peptide synthesis. HATU (2-(7-Aza-1 H-benzotriazole-1 -yl)-1 ,1 ,3,3-tetramethyluronium
hexafluorophosphate) and PEG4 (Fmoc-NH-PEG4-CH2CH2COOH, Fmoc-18-amino- 4,7,10,13, 16-pentaoxaoctadecanoic acid) were purchased from ChemPep. DIEA (diisoproylethylamine), triethylsilane (TES) and TFA (Trifluoroacetic acid) were purchased from Sigma Aldrich. TentaGel beads were purchased as 90μιτι S-NH2 beads, 0.29mmol/g, 2.86x1 06 beads/g from Rapp Polymere (Germany), Rink Amide resin was purchased from Anaspec and C-terminal biotinylated peptides were synthesized on Biotin NovaTag resin (EMD Millipore).
[00181] Cyclic Peptide Library Construction
[00182] Cyclic peptide libraries were synthesized on a Titan 357 split-and-mix automated peptide synthesizer (Aapptec) via standard FMOC SPPS coupling chemistry using 90μιτι TentaGel S-NH2 beads. All cyclic libraries included a C- terminal Lys(N3) residue, 18 L-stereoisomers of the natural amino acids, minus Cysteine and Methionine, at each of five randomized positions followed by a
Propargylglycine residue. Libraries were cyclized overnight at RT after synthesis with 1 .5 eq. Cul and 5 eq. L-ascorbic acid in 20% piperidine:NMP. Resin was chelated extensively with 5% w/v sodium diethyldithiocarbamate trihydrate and 5% v/v DIEA in NMP. For the in situ click screen, an azide or alkyne click handle was coupled to the N-terminus following cyclization. At least a five-fold excess of beads is used when synthesizing libraries to ensure oversampling of each sequence. Amino acid side-chains are protected by TFA labile protecting groups that are removed all at once following library synthesis using using a 95:5:5 ratio of TFA: H20: TES.
[00183] Scaled Up Peptide Synthesis
[00184] Bulk synthesis of peptide sequences was performed using standard FMOC SPPS peptide chemistry on either the Titan 357 automated peptide synthesizer (AAPPTEC) or a Liberty 1 microwave peptide synthesizer (CEM Corporation). The typical scale was 300mg on Rink Amide Resin, unless otherwise noted. Click cyclized peptides were cyclized overnight at RT after synthesis with 1 .5 eq. Cul and 5 eq. L-ascorbic acid in 20% piperidine:NMP. Resin was chelated extensively with 5% w/v sodium diethyldithiocarbamate trihydrate and 5% v/v DIEA in NMP. Peptides were cleaved from the beads with deprotected side-chains using a 95:5:5 ratio of TFA: H20: TES. The peptides were purified on a prep-scale Dionex U3000 HPLC with a reverse-phase C18 column (Phenomenex). All peptides are checked for correct mass and impurities using MALDI-TOF MS and are lyophilized to a powder for long-term storage at room temperature. Concentrated peptide stocks for assays are made by dissolving powder in small amounts of DMSO and measuring the A280 absorbance via Nanodrop to determine the stock concentration.
[00185] 3io Helix Click-stabilized Inhibitor Variant Synthesis
[00186] The peptidomimetic inhibitor Dab(Dinitrophenol)-RWT-Dab-ML as reported by Zuniga et al., (201 1 ) was scaled up as outlined above with a C-terminal PEG4 biotin and an N-terminal PEG4 biotin. The N-terminally labeled variant showed no detectable binding in a point ELISA format or inhibition in an in vitro BoNT LC activity assay, this is consistent with the crystal structure indicating a partially buried N- terminus when bound. The C-terminally labeled variant was used as a control during the screening of various cyclic variants (Figure 17). Sixteen variants were
synthesized. All were based on the inhibitor above, with an (i, i+3) substitution of propargylglycine and azidolysine. Both possible arrangements of these residues were tested for each substitution as well as an up to two residue glycine extension on the C-terminus. All compounds were cyclized as detailed above.
[00187] Sandwich ELISA Assays for Initial Evaluation of BoNT LC Binding
[00188] These assays were conducted to test the binding of the various ligands to the BoNT LC protein. For this assay, all samples were taken in triplicate for statistical purposes. The target protein used was BoNT LC— GST conjugate (List Labs).
Peptide ligands were first immobilized onto Neutravidin ELISA plates (Pierce) for one hour at 1 μΜ concentration. A PEG4-biotin, was used as the no-ligand blank, as the GST proteins has significant background binding to a blank Neutravidin plate. The plates were then blocked with 5% BSA overnight. Protein was incubated at a concentration of 100nM for samples wells and the blank wells. GST protein alone (Abeam) was also incubated with the ligands and blanks as a control. The proteins were incubated for three hours at room temperature, then washed three times with 1 xTBS + 0.05% Tween-20. The protein was then detected with 1 :1 0,000 anti-GST mouse mAb (Fisher) for one hour, washed three times with 1 xTBS + 0.05% Tween- 20 and developed with a 1 :1 mixture of TMB substrate for ten minutes. The samples were plotted by subtracting the blanks and averaging the sample wells, when included error bars indicate one standard deviation above and below.
[00189] FRET-based in vitro BoNT-LC Activity Assay
[00190] FRET-based BoNT-LC activity assays were carried out as suggested by the manufacturer of the FRET pair labeled BoNT substrate (List Labs, SNAPtide #523). All time-resolved fluorescence assays were performed in a Flexstation3 fluorescent plate reader at 37 degrees. Briefly, 8 μΜ of FRET-labeled substrate was prepared in Assay Buffer (50 mM HEPES, pH 7.4, containing 0.3 mM ZnCI2, 1 .25 mM DTT and 0.05% Tween-20) in a black fluorescence 96-well plate. BoNT LC-GST conjugate was diluted to the indicated concentration (generally 1 nM unless noted otherwise) and preincubated either with the indicated concentration of inhibitory peptide ligand, or a 0.05% DMSO control. At time = 0, the plate reader adds the BoNT-LC to the substrate, and begins monitoring the fluorescence. The excitation wavelength was set to 490 nm, and the emission to 523 nm with a cutoff at 495 nm. Wells were monitored for approximately one hour. Initial velocities of cleavage were plotted against inhibitor concentration.
[00191] Fluorescence Polarization Assays
[00192] lnh-1 and L2 were synthesized with fluorescein for fluorescence polarization (FP) assays. The BoNT LC binding assays were completed by making a 1 μΜ starting protein concentration and diluting 3x in Assay Buffer down a series of 10 wells in a black 96 well polystyrene plate. Ligand was added to the wells for a final concentration of 20nM. The plate was incubated at room temperature for one hour with shaking, and read on a Flexstation3 plate reader.
[00193] The data were fitted by subtracting the average of the low concentration baseline to zero in order to use the Hill fit. Using GraphPad Prism, the curves were fitted to a Hill function using a common saturation point.
[00194] Secondary Binder Epitope-Targeted Screen
[00195] Screens were performed using a library with the form Pra-Pra-XXXXX- Lys(N3)-TG, with the azido and propargyl amino acids closest to the bead clicked together to form a closed cycle. The peptide library was a comprehensive 5-mer containing 18 L-amino acids, excluding Met and Cys due to stability reasons. The N- terminus contained an alkyne amino acid for in situ click with the Lys(N3) on the target 13-mer-epitope fragment. Screens were performed using 400mg of dried library beads swelled at least six hours in 1 x TBS (25mM Tris-CI, 1 50mM NaCI, 10mM MgCI2, pH = 7.5) buffer and blocked in Blocking Buffer (1 x TBS + 1 % BSA + 0.05% Tween-20) overnight. Screening against the BoNT LC 1 66-1 79 epitope was carried out in two main steps: a scrambled epitope pre-clear and a target epitope product screen.
[00196] Step 1 : Scrambled Epitope Preclear
[00197] Swelled library beads were blocked overnight in blocking buffer then washed with 1 x TBS three times. The scrambled epitope (Lys(N3)-NGTLFNLSEVRH-PEG4- Biotin) Figure 1 5) was added at a concentration of 5μΜ in Blocking Buffer and incubated shaking at room temperature for four hours. The beads were washed three times with Blocking Buffer. 1 :10 000 Mouse mAb anti-Biotin alkaline
phosphatase conjugate (Abeam) was added in Blocking Buffer for one hour, followed by three washes in Blocking Buffer, three washes 1 x TBS + 0.05% Tween-20, and three 15 minute washes with a high-salt TBS buffer (1 x TBS with 750mM NaCI), then let shake in high salt buffer for one hour. The beads were then washed three times with BCIP buffer (1 OOmM Tris-CI, 150mM NaCI, 1 mM MgCI2, pH = 9.0) and developed by adding 1 5ml_ BCIP buffer plus 13pL BCIP and 26pL NBT (two part system, Promega). Development proceeded for 30 minutes. After development the beads were quenched with concentrated HCI to 0.1 N and washed with MilliQ water ten times to remove substrate. Beads were placed in a plate in 0.05N HCI. The purple beads (typically approximately 1 -5%) were removed by micropipette and discarded. The remaining beads were incubated in NMP 4 hours to remove trace purple precipitate from the BCIP/NBT reaction, then were washed five times with methanol, five times with water, five times with 1 xTBS and reblocked overnight in Blocking Buffer.
[00198] Step 2: Target Epitope Product Screen
[00199] Beads remaining from the preclear were washed three times with Blocking Buffer, then incubated with 5μΜ of the target epitope (Lys(N3)-SFGHEVLNLTRN, Figure 14) in Blocking Buffer for 12 hours to allow for an in situ click reaction to occur. The beads were then washed three times with 1 X TBS and incubated for 1 hr with a 7.5M Guanadine-HCI buffer (pH = 2.0) to remove all target epitope not attached covalently to the beads. These beads were then washed ten times with 1 x TBS, reblocked overnight in Blocking Buffer, then incubated for one hour with a 1 :1 0 000 Mouse mAb anti-Biotin alkaline phosphatase conjugate (Abeam) in Blocking buffer for 1 hr to detect for the presence of the biotinylated target epitope clicked to the hit beads. Antibody incubation was followed by three washes in Blocking Buffer, three washes 1 x TBS + 0.05% Tween-20, and three 15 minute washes with a high-salt TBS buffer (1 x TBS with 750mM NaCI), then let shake in high salt buffer for one hour. Afterwards, the beads were again washed three times in BCIP buffer and developed as per the preclear. Purple beads are removed from the screen via pipette as hit beads. These hits were incubated in the guanidine-HCI buffer to remove attached streptavidin, washed ten times with water and sequenced via edman degradation on a Procise CLC system from Applied Biosystems. See Table SX for sequences from product screen.
[00200] Kinetic in situ click target-guided synthesis of divalent inhibitor
[00201] This screen was performed using a library with the form Pra-XXXXX-Pra- NYRWL-Lys(N3)-TG, with the azido and propargyl amino acids closest to the bead clicked together to form a closed cycle. The peptide library was comprehensive from length zero to length five containing only four possible residues (Glycine, D-Leucine, Aminoisobutyrate and D-Proline, see Figure 2). The N-terminus contained an alkyne amino acid for in situ click with the lnh-1— Biotin— Lys(N3) anchor inhibitor (Figure 17). Screens were performed using 50 mg of dried library beads swelled at least six hours in 1 x TBS (25mM Tris-CI, 150mM NaCI, 10mM MgCI2, pH = 7.5) buffer and blocked in Blocking Buffer (1 x TBS + 1 % BSA + 0.05% Tween-20) overnight.
Screening was performed with the lnh-1— Biotin— Lys(N3) anchor inhibitor compound and the BoNT LC protein.
[00202] Step 1 : lnh-1 Interaction Preclear
[00203] Swelled library beads were blocked overnight in blocking buffer then washed with 1 x TBS three times. The anchor inhibitor (lnh-1— Biotin— Lys(N3)) Figure 17) was added at a concentration of 10μΜ in Blocking Buffer and incubated shaking at room temperature for four hours. The beads were washed three times with Blocking Buffer. 1 :10 000 Mouse mAb anti-Biotin alkaline phosphatase conjugate (Abeam) was added in Blocking Buffer for one hour, followed by three washes in Blocking Buffer, three washes 1 x TBS + 0.05% Tween-20, and three 15 minute washes with a high-salt TBS buffer (1 x TBS with 750mM NaCI), then let shake in high salt buffer for one hour. The beads were then washed three times with BCIP buffer (100mM Tris-CI, 150mM NaCI, 1 mM MgCI2, pH = 9.0) and developed by adding 15ml_ BCIP buffer plus 13pL BCIP and 26pL NBT (two part system, Promega). Development
proceeded for 30 minutes. After development the beads were quenched with concentrated HCI to 0.1 N and washed with MilliQ water ten times to remove substrate. Beads were placed in a plate in 0.05N HCI. The purple beads
(approximately 1 %) were removed by micropipette and discarded. The remaining beads were incubated in NMP 4 hours to remove trace purple precipitate from the BCIP/NBT reaction, then were washed five times with methanol, five times with water, five times with 1 xTBS and reblocked overnight in Blocking Buffer.
[00204] Step 2: Target-guided Synthesis Product Screen
[00205] Beads remaining from the preclear were washed three times with Blocking Buffer, then incubated with 10μΜ of the anchor inhibitor (lnh-1— Biotin— Lys(N3)) Figure 17) and 10OnM BoNT LC in Blocking Buffer for either 2 or 12 hours to allow for an in situ click reaction to occur. The beads were then washed three times with 1 X TBS and incubated for 1 hr with a 7.5M Guanadine-HCI buffer (pH = 2.0) to remove all lnh-1 not attached covalently to the beads. These beads were then washed ten times with 1 x TBS, reblocked overnight in Blocking Buffer, then incubated for one hour with a 1 :10 000 Mouse mAb anti-Biotin alkaline phosphatase conjugate (Abeam) in Blocking buffer for 1 hr to detect for the presence of the biotinylated lnh-1 clicked to the hit beads. Antibody incubation was followed by three washes in Blocking Buffer, three washes 1 x TBS + 0.05% Tween-20, and three 15 minute washes with a high-salt TBS buffer (1 x TBS with 750mM NaCI), then let shake in high salt buffer for one hour. Afterwards, the beads were again washed three times in BCIP buffer and developed as per the preclear. Purple beads are removed from the screen via pipette as hit beads. These hits were incubated in the guanidine-HCI buffer to remove attached streptavidin, washed ten times with water and sequenced via edman degradation on a Procise CLC system from Applied Biosystems. See Figure 16 for sequences from product screen.
[00206] iCell Neuron Culture [00207] The cryopreserved hiPSC-derived neurons (iCell Neurons) were supplied by Cellular Dynamics International. The neurons were an— 98% pure (Tuj1 +/Nestin-) pan-neuronal population of GABAergic, glutamatergic, and a very small percentage (< 1 %) of dopaminergic neurons. Neurons were thawed according to the provided instructions, and live cells were counted by the Trypan Blue exclusion method. Cells were seeded at a density of 50,000 cells per well into Poly-D-Lysine Coated 96 Well plates (Corning) and 8.3 μg/cm2 human Laminin (Sigma) unless otherwise indicated and incubated in neuronal medium with supplement as provided by Cellular
Dynamics International. 50% of the medium was replaced every 3 days. Neural outgrowth staining (Life Technologies) showed substantial neurite growth and maturation 3 days after plating (Figure S1 6). Active synaptic vesicle recycling upon K7Ca2+ depolarization was monitored by FM1 -43 (Life Technologies) staining and nearly all neurons showed repeatable staining and destaining by day 15 after plating (Figure 22A-D).
[00208] Neuronal BoNT Toxicity Assays
[00209] For all neuronal toxicity assays, 3 day post plating hiPSC-derived neurons were exposed to the indicated concentrations of BoNT/A holotoxin (List Labs) with indicated inhibiting compounds in 50μ\- of neuronal medium allowed to pre-incubate for 1 hr at 37 degrees. A negative control without toxin was always included. After 24 hours of exposure time, the toxin solution was removed and cells were lysed in 50 μΙ of 1 x lithium dodecyl sulfate (LDS) loading buffer (Invitrogen). The cell lysates were analyzed by western blot for SNAP-25 cleavage and beta-tubulin as a loading control. SNAP-25 was probed using Ms anti-SNAP-25 SMI-81 (Abeam) as a primary and goat anti-Ms H&L Alexafluor 790 (Life Technologies) as a secondary and imaged using an Odyssey instrument at the 800 nm wavelength. Beta Tubulin was probed using Rb anti-beta Tubulin (Life Technologies) as a primary and goat anti-Rb H&L Alexafluor 680 (Life Technologies) as a secondary and imaged using an Odyssey instrument at the 700 nm wavelength. Cleaved SNAP-25 bands appeared below the intact SNAP-25 band, and each were quantified by densitometry in ImageJ and the relative fraction of intact SNAP-25 indicated in Figures 4A-4B and 5A-3C.
[00210] For protection assays, neurons were cultured and exposed to toxin as indicated above. At the indicated times, 10 μ\- of neuronal medium spiked with inhibitory compounds were added at an appropriate concentration to bring the total concentration in the well to 1 μΜ in a total volume of 60 μΙ_. As above, 24 hours post exposure all cells were lysed with 1 x LDS and analyzed by western blot.
[00211] Synaptic Vesicle Recycling Assays
[00212] hiPSC-derived neurons were cultured as indicated above and allowed to mature, with 50% replacement of neuronal medium every three days. After 1 5 days, the neurons showed synaptic vesicle staining and destaining using FM1 -43 dye followed by K7Ca2+ depolarization. These matured neuron cultures were exposed to the indicated BoNT/A holotoxin pre-incubated with inhibitor as indicated, and were then assayed with FM1 -43.
[00213] For FM1 -43 loading, control and toxin/inhibitor-exposed neurons were washed in Hank's Balanced Salt Solution (HBSS) and depolarized for 5 min at 37 degrees with 56 mM KCI in isosmotic HBSS containing 2 mM CaCI2 and 2 mM FM1 - 43 (Life Technologies). Cultures were washed twice for 10 minutes in HBSS without Ca2+ and containing 0.5 mM EGTA, to wash surface membranes of the dye while preventing neuronal activation and loss of FM1 -43 from within already labeled terminals. Labeled neurons were imaged in this rinse solution; some wells underwent a second round of depolarization (in the absence of FM1 -43) to destain synaptic terminals and evaluate functional intoxication. Before imaging, all conditions were given a last wash with the suggested dilution of NucRed Live 647 live cell nuclear stain (Life Technologies). FM1 -43 labeled cultures were photographed using an EVOS FL microscope. FM1 -43 could be monitored on the RFP/GFP channels and the NucRed stained was monitored on the Cy5 channel.
[00214] Images were analyzed by ImageB. We used a watershed analysis to find the edges of neuron cell bodies in the transmission channel and allocate a given intercellular area to each cell. These areas were then mapped onto the FM1 -43 layer and puncta were counted in each area using the PunctaAnalyzer package while ignoring the previously identified cell bodies to find only synaptic vesicle puncta along neurites. The puncta count for each cell was averaged over two wells with two fields of view per well. A typical analysis is shown in Figure 23.
[00215] Cell Penetration of STP-DBCO-Cy5
[00216] The spontaneously translocated peptide (pliylrllrGqf) previously reported was synthesized from D-stereoisomer amino acids with an N-terminal Lys(N3). DBCO-Cy5 was then coupled to the azide with 1 .1 eq. using strain-promoted click chemistry in DMF overnight. To verify that this peptide could delivery a sizeable polar cargo to the neuronal cytosol, STP-DBCO-Cy5 was diluted to 1 μΜ concentration in neuronal media and added to the neurons for 30 minutes. After incubation the cells were washed once with neuronal medium and 2x with HBSS. One final wash was given with the suggested dilution of NucBlue Live Readyprobe (Life Technologies) in order to visualize the cell nuclei. Neurons were imaged live with an EVOS FL microscope system. NucBlue could be monitored on the DAPI channel, STP-DBCO- Cy5 could be monitored on the Cy5 channel. A representative view of cell showing Cy5 in the cytosol is shown in Figure 24.
[00217] Synthesis of lnh-2 and lnh-2-STP Peptide Bicycles
[00218] Compound lnh-2 was synthesized on Rink Amide resin beginning with the synthesis of the L-2 cyclic peptide NH2-Pra-NYRWL-Lys(N3) on resin. This peptide was cyclized and chelated as detailed previously. The linker region was then coupled resulting in the compound NH2-G-Aib-l-[Pra-NYRWL-Lys(N3)] where square brackets indicate a closed cycle. The custom "Tz4" residue Fmoc-Lys(N3-Boc-Pra-OH)-Otbu was then coupled on resin. After Fmoc deprotection, either Fmoc-Lys(Mtt)-OH or Fmoc-Lys(Biotin)-OH (both Chempep) were then coupled depending on whether an orthogonally addressable amine or a biotin handle is needed (for lnh-2 and lnh-2- STP respectively). After Fmoc deprotection, the lnh-1 peptide is coupled as detailed previously resulting in the compound NH2-Dab(DNP)-R-Lys(N3)-T-Dab(Boc)-Pra-L- Lys(MTT or Biotin) - Tz4-G-Aib-l-[Pra-NYRWL-Lys(N3)] where square brackets indicate a closed cycle. This compound is then cyclized and chelated again as detailed above to create the bicyclic compound. For lnh-2-STP synthesis, the MTT protecting group is removed from the Lys(MTT) by 10 washes with 1 % TFA in DCM. The protection group removal was monitored by the yellow color of the eluent.
DBCO-acid (Sigma) was coupled to the free amine, and STP (see synthesis above) was coupled with 1 .1 eq. using strain-promoted click chemistry in DMF overnight. This peptide is cleaved as normal with 95:5:5 TFA:H2O:TES and purified by reverse phase HPLC. The structure and MALDI-TOF spectrum of these compounds can be found in Figures 10, 18 and 20.

Claims

What is claimed is:
1 . A stable, synthetic capture agent that specifically binds botulinum neurotoxin serotype A protein, wherein the botulinum neurotoxin serotype A protein comprises a heavy chain and a light chain, wherein the light chain comprises an enzymatic active site, wherein the capture agent comprises a anchor ligand and a secondary ligand and wherein the ligands specifically bind the botulinum neurotoxin serotype A protein.
2. The capture agent of claim 1 , wherein the anchor ligand specifically binds to the enzymatic active site.
3. The capture agent of claim 2, wherein the anchor ligand comprises a cyclic peptide comprising the formula of Dab(DNP)-R-Lys(N3)-T-Dab-Pra-L-NH-
4. The capture agent of claim 3, wherein the anchor ligand comprises a molecule of formula lnh-1
Figure imgf000058_0001
wherein R1 is absent or is a linker to the secondary ligand.
5. The capture agent of claim 1 , wherein the secondary ligand specifically binds to a site on the botulinum neurotoxin serotype A protein that is 3-10 angstroms away from the enzymatic active site of the botulinum neurotoxin serotype A protein.
6. The capture agent of claim 5, wherein the secondary ligand specifically binds the botulinum neurotoxin serotype A light chain.
7. The capture agent of claim 6, wherein the secondary ligand specifically binds an occluded conformation of the botulinum neurotoxin serotype A holotoxin.
8. The capture agent of claim 7, wherein the secondary ligand specifically binds residues 166-179 of the botulinum neurotoxin serotype A light chain.
9. The capture agent of claim 1 , wherein the secondary ligand comprises a cyclic peptide comprising the formula of -Pra-NYRWL-Lys(NS).
10. The capture agent of claim 1 , wherein the secondary ligand comprises a molecule of formula L2
Figure imgf000059_0001
wherein R2 is absent or is a linker to the anchor ligand.
1 1 . The capture agent of any one of the preceding claims further comprising a linker.
12. The capture agent of claim 1 1 , wherein the linker is a tripeptide.
13. The capture agent of claim 12, wherein the linker comprises the amino acid sequence of Gly-Aib-Leu or Leu-Aib-Gly.
14. The capture agent of claim 13, wherein the linker comprises the amino acid sequence of Gly-Aib-Leu.
15. The capture agent of claim 13, wherein the linker comprises the amino acid sequence of Leu-Aib-Gly.
8
16. The capture agent of claim 1 1 , wherein the linker comprises PEG4.
17. The capture agent of claim 1 1 , wherein the anchor ligand and/or the
secondary ligand are linked to the linker via a 1 ,4-substituted-1 ,2,3-triazole residue (Tz4) or via a 1 ,5-substituted-1 ,2,3-triazole residue (Tz5).
18. The capture agent of claim 17, wherein the anchor ligand is linked to the linker via a Tz4.
19. The capture agent of claim 1 , wherein the capture agent comprises a molecule of formula lnh-2
Figure imgf000060_0001
wherein R3 is hydrogen, a capping group, or comprises a label or a spontaneously translocating peptide.
20. The capture agent of claim 19, wherein the label is selected from the group consisting of biotin, copper-DOTA, biotin-PEG3, aminooxyacetate, 9FB, 8FB, 5- carboxyfluorescein, and FITC-PEG3.
21 . The capture agent of claim 19, wherein the label is a detectable moiety selected from the group consisting of 64Cu DOTA, 68Ga DOTA, 68Ga NOTA, 18F, AI18F NOTA, 64Cu, 68Ga, 89Zr, 124l, 86Y, 94mTc, 110mln, 11C and 76Br.
22. The capture agent of claim 19, wherein the spontaneously translocating peptide comprises the amino acid sequence of pliylrllrGqf.
23. The capture agent of any one of claims 1 -22 for use in inhibiting SNAP-25 cleavage mediated by botulinum neurotoxin serotype A protein.
24. The capture agent of claim 23, wherein the capture agent is also linked to a spontaneously translocating peptide.
25. The capture agent of claim 24, wherein the spontaneously translocating peptide comprises the amino acid sequence of pliylrllrGqf.
26. The capture agent of any one of claims 1 -17 for use in treatment of botulism.
27. The capture agent of claim 26, wherein the capture agent is also linked to a spontaneously translocating peptide.
28. The capture agent of claim 27, wherein the spontaneously translocating peptide comprises the amino acid sequence of pliylrllrGqf.
29. A method of synthesizing a capture agent to a target peptide comprising the steps of:
a. identifying an anchor ligand and a secondary ligand that bind to the same target peptide at distinct epitopes;
b. identifying the binding sites of the anchor ligand and the secondary ligand on the target peptide;
c. calculating the distance between the binding site of the anchor ligand and the secondary ligand;
d. selecting a linker to connect the anchor ligand to the secondary ligand, thereby generating a capture agent, wherein the dissociation constant of the capture agent for binding to the target protein is lower than the dissociation constant of either the anchor ligand or the secondary ligand for binding to the target protein; and e. synthesizing the capture agent comprising the anchor ligand and secondary ligand of step (a) and the linker of step (d).
30. The method of claim 29, wherein the linker has a length that is within 10% of the distance between the anchor ligand and the secondary ligand when both ligands are bound to the target protein.
31 . A method of synthesizing a capture agent for inhibiting SNAP-25 cleavage mediated by botulinum neurotoxin serotype A protein in one or more neurons, wherein the botulinum neurotoxin serotype A protein comprises a heavy chain and a light chain, wherein the light chain comprises an enzymatic active site, comprising a. selecting an anchor ligand that specifically binds to the enzymatic active site of the botulinum neurotoxin serotype A protein;
b. selecting a secondary ligand that specifically binds at a distinct epitope from the anchor ligand within 5-10 angstroms on the botulinum neurotoxin serotype A protein; and
c. linking the anchor ligand and secondary ligand together,
wherein, the secondary ligand must bind to an epitope so that it specifically binds to an occluded conformation of the botulinum neurotoxin serotype A holotoxin, thereby synthesizing the capture agent for inhibiting SNAP-25 cleavage mediated by botulinum neurotoxin serotype A protein in one or more neurons.
32. The method of claim 31 , wherein the linking of the anchor ligand and the secondary ligand is performed using a linker.
33. The method of claim 32, wherein the linker has a length that is within 10% of the distance between the anchor ligand and the secondary ligand when both ligands are bound to the botulinum neurotoxin serotype A protein.
34. The capture agent of any one of claims 1 -22 for use as a medicament.
PCT/US2016/022693 2015-03-16 2016-03-16 Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making WO2016149404A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201680016366.5A CN107624115B (en) 2015-03-16 2016-03-16 Botulinum neurotoxin specific capture agents, compositions, methods of use, and methods of manufacture
EP16713229.9A EP3270951B1 (en) 2015-03-16 2016-03-16 Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562133891P 2015-03-16 2015-03-16
US62/133,891 2015-03-16

Publications (1)

Publication Number Publication Date
WO2016149404A1 true WO2016149404A1 (en) 2016-09-22

Family

ID=55642896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/022693 WO2016149404A1 (en) 2015-03-16 2016-03-16 Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making

Country Status (4)

Country Link
US (3) US9913875B2 (en)
EP (1) EP3270951B1 (en)
CN (1) CN107624115B (en)
WO (1) WO2016149404A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214447A1 (en) * 2016-06-08 2017-12-14 Children's Medical Center Corporation Engineered botulinum neurotoxins

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180077343A (en) * 2012-11-21 2018-07-06 입센 바이오이노베이션 리미티드 Methods for the manufacture of proteolytically processed polypeptides
CN107624115B (en) 2015-03-16 2021-10-26 加州理工学院 Botulinum neurotoxin specific capture agents, compositions, methods of use, and methods of manufacture
WO2018064597A1 (en) 2016-09-29 2018-04-05 Indi Molecular, Inc. Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
EP3638687A1 (en) 2017-06-15 2020-04-22 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
US11638764B2 (en) * 2018-11-08 2023-05-02 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
WO2022098745A1 (en) * 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006605A1 (en) 1985-05-08 1986-11-20 The General Hospital Corporation Hepatobiliary nmr contrast agents
WO1991003200A1 (en) 1989-08-28 1991-03-21 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic nmr imaging
WO1995028179A1 (en) 1994-04-15 1995-10-26 Metasyn, Inc. Contrast agents for diagnostic imaging
WO1995028967A1 (en) 1994-04-20 1995-11-02 Nycomed Salutar Inc Contrast agents
US5474756A (en) 1986-01-23 1995-12-12 Bracco International B.V. Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
WO1996023526A2 (en) 1995-02-01 1996-08-08 Epix Medical, Inc. Diagnostic imaging contrast agents with extended blood retention
WO1997036619A2 (en) 1996-04-01 1997-10-09 Epix Medical, Inc. Bioactivated diagnostic imaging contrast agents
WO1998018497A2 (en) 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
WO1998018496A2 (en) 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
WO2009155420A1 (en) * 2008-06-18 2009-12-23 California Institute Of Technology Multi-ligand capture agents and related compositions, methods and systems
WO2012106671A1 (en) 2011-02-03 2012-08-09 Integrated Diagnostics, Inc. Psa capture agents, compositions, methods and preparation thereof
WO2013009869A2 (en) 2011-07-11 2013-01-17 Integrated Diagnostics, Inc. Akt-specific capture agents, compositions, and methods of using and making
WO2013033561A1 (en) 2011-08-31 2013-03-07 Integrated Diagnostics, Inc. Vegf-specific capture agents, compositions and methods of using and making
WO2014074907A1 (en) 2012-11-09 2014-05-15 Indi Molecular, Inc. C-met-specific capture agents, compositions, and methods of using and making
US9801473B2 (en) 2012-09-13 2017-10-31 Kids Ii, Inc. Play yard with removable liner
US9820182B2 (en) 2013-07-12 2017-11-14 Telefonaktiebolaget Lm Ericsson (Publ) Method for enabling control of data packet flows belonging to different access technologies

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547668A (en) 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
US5919967A (en) 1997-04-11 1999-07-06 Epix Medical, Inc. Process for synthesizing phosphodiesters
BR9812716A (en) 1997-10-02 2000-08-22 Epix Medical Inc Imaging methods for enhanced contrast diagnosis to monitor interventional therapies
GB9722779D0 (en) 1997-10-28 1997-12-24 Isis Innovation Human CD8 as an inhibitor of the cellular immune system
US6667158B1 (en) * 1998-12-17 2003-12-23 The United States Of America As Represented By The Secretary Of The Army Antibodies against type a botulinum neurotoxin
EP1379250A2 (en) 2001-04-10 2004-01-14 Merck & Co., Inc. A method of treating cancer
AU2002322466B2 (en) 2001-07-11 2007-08-30 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
JP2005539067A (en) 2002-09-16 2005-12-22 エリューシス セラピューティクス，インコーポレーテッド Production of bispecific molecules using polyethylene glycol linkers
WO2005113762A1 (en) 2004-05-18 2005-12-01 Pfizer Products Inc. CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF
WO2007050963A1 (en) 2005-10-27 2007-05-03 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use thereof
GB0720118D0 (en) 2007-10-15 2007-11-28 Achour Adnane Modified mhc class 1 binding peptides
WO2009105746A2 (en) 2008-02-22 2009-08-27 University Of South Florida Triazoles and processes for producing the same
JP6053517B2 (en) 2009-05-05 2016-12-27 ノヴィミュンヌ エスア Anti-IL-17F antibodies and methods for their use
WO2010135431A2 (en) 2009-05-19 2010-11-25 The Regents Of The University Of California Compositions, devices, and methods related to prostate-specific membrane antigen
WO2011057347A1 (en) 2009-11-12 2011-05-19 Tgr Biosciences Pty Ltd Analyte detection
US10108386B2 (en) 2011-02-04 2018-10-23 Qualcomm Incorporated Content provisioning for wireless back channel
ES2538694T3 (en) 2011-04-01 2015-06-23 F. Hoffmann-La Roche Ag Variants of the T7 RNA polymerase with Cysteine-Serine substitutions
WO2013034982A2 (en) 2011-09-09 2013-03-14 The University Of British Columbia Immunomodulatory peptides for treatment of progressive neurodegenerative diseases
NZ702310A (en) * 2012-05-30 2016-08-26 Harvard College Engineered botulinum neurotoxin
RU2015113348A (en) 2012-10-08 2016-11-27 Ф. Хоффманн-Ля Рош Аг CELLING PEPTIDES IN CELLS BINDING INTERFERON-REGULATING FACTOR 5
EP2719706A1 (en) * 2012-10-15 2014-04-16 Universität Zürich Bispecific HER2 ligands for cancer therapy
EP3010550B1 (en) 2013-06-20 2021-10-27 California Institute of Technology Cyclic peptides as protein targeting agents
WO2015038904A1 (en) 2013-09-12 2015-03-19 California Institute Of Technology Anti-gp41 antibody-specific capture agents, compositions, and methods of using and making
US20150344523A1 (en) 2014-05-05 2015-12-03 California Institute Of Technology Mutant akt-specific capture agents, compositions, and methods of using and making
CN107624115B (en) 2015-03-16 2021-10-26 加州理工学院 Botulinum neurotoxin specific capture agents, compositions, methods of use, and methods of manufacture
US10598671B2 (en) 2015-07-15 2020-03-24 Indi Molecular, Inc. IL-17F-specific capture agents, compositions, and methods of using and making
EP3440101B1 (en) 2016-04-04 2021-10-06 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
WO2018064597A1 (en) 2016-09-29 2018-04-05 Indi Molecular, Inc. Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
JP2020513418A (en) 2016-12-13 2020-05-14 エモリー ユニバーシティ Polypeptides for controlling viral infections
WO2018170096A1 (en) 2017-03-14 2018-09-20 Dualogics, Llc Use of a cd4/cd8 bispecific antibody for the treatment of diabetes
US20210100920A1 (en) 2017-04-24 2021-04-08 Case Western Reserve University Methods and agents for the detection and treatment of cancer
EP3749676A4 (en) 2018-02-09 2021-12-22 Healthtell Inc. Array-based cyclic peptide libraries
EP3898233B1 (en) 2018-12-17 2024-04-10 PolyCine GmbH Flexible multilayer film with uv-vis barrier layer for medical packaging
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006605A1 (en) 1985-05-08 1986-11-20 The General Hospital Corporation Hepatobiliary nmr contrast agents
US4899755A (en) 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
US5846519A (en) 1986-01-23 1998-12-08 Bracco Diagnostics Inc. Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5474756A (en) 1986-01-23 1995-12-12 Bracco International B.V. Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US6143274A (en) 1986-01-23 2000-11-07 Tweedle; Michael F. Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
WO1991003200A1 (en) 1989-08-28 1991-03-21 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic nmr imaging
WO1995028179A1 (en) 1994-04-15 1995-10-26 Metasyn, Inc. Contrast agents for diagnostic imaging
WO1995028967A1 (en) 1994-04-20 1995-11-02 Nycomed Salutar Inc Contrast agents
WO1996023526A2 (en) 1995-02-01 1996-08-08 Epix Medical, Inc. Diagnostic imaging contrast agents with extended blood retention
WO1997036619A2 (en) 1996-04-01 1997-10-09 Epix Medical, Inc. Bioactivated diagnostic imaging contrast agents
WO1998018496A2 (en) 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
WO1998018497A2 (en) 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
WO2009155420A1 (en) * 2008-06-18 2009-12-23 California Institute Of Technology Multi-ligand capture agents and related compositions, methods and systems
US20100009896A1 (en) 2008-06-18 2010-01-14 Agnew Heather Capture agents and related compositions, methods and systems
WO2012106671A1 (en) 2011-02-03 2012-08-09 Integrated Diagnostics, Inc. Psa capture agents, compositions, methods and preparation thereof
WO2013009869A2 (en) 2011-07-11 2013-01-17 Integrated Diagnostics, Inc. Akt-specific capture agents, compositions, and methods of using and making
WO2013033561A1 (en) 2011-08-31 2013-03-07 Integrated Diagnostics, Inc. Vegf-specific capture agents, compositions and methods of using and making
US9801473B2 (en) 2012-09-13 2017-10-31 Kids Ii, Inc. Play yard with removable liner
WO2014074907A1 (en) 2012-11-09 2014-05-15 Indi Molecular, Inc. C-met-specific capture agents, compositions, and methods of using and making
US9820182B2 (en) 2013-07-12 2017-11-14 Telefonaktiebolaget Lm Ericsson (Publ) Method for enabling control of data packet flows belonging to different access technologies

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ALEXANDER, A. ET AL., MAGN. RESON. MED., vol. 40, 1998, pages 298 - 310
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 402
BLAKE FARROW ET AL: "Epitope Targeting of Tertiary Protein Structure Enables Target-Guided Synthesis of a Potent In-Cell Inhibitor of Botulinum Neurotoxin", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 54, no. 24, 29 April 2015 (2015-04-29), DE, pages 7114 - 7119, XP055272540, ISSN: 1433-7851, DOI: 10.1002/anie.201502451 *
BUNDGARD, H.: "Design of Prodrugs", 1985, ELSEVIER, pages: 7 - 9,21-24
CLAVERIE; STATES, COMPUT. CHEM., vol. 17, 1993, pages 191 - 201
EDELMAN, R. ET AL., RADIOLOGY, vol. 177, 1990, pages 45 - 50
GOODRICH, K. ET AL., INVEST. RADIA, vol. 31, 1996, pages 323 - 32
HIGUCHI, T. ET AL.: "A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design", vol. 14, 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
MA H ET AL: "A cyclic peptide-polymer probe for the detection of Clostridium botulinum neurotoxin serotype A", TOXICON, ELMSFORD, NY, US, vol. 47, no. 8, 15 June 2006 (2006-06-15), pages 901 - 908, XP025007854, ISSN: 0041-0101, [retrieved on 20060615], DOI: 10.1016/J.TOXICON.2006.03.003 *
MATTHEW B. COPPOCK ET AL: "Peptide-based protein capture agents with high affinity, selectivity, and stability as antibody replacements in biodetection assays", OPTICAL SENSING II, vol. 9107, 22 May 2014 (2014-05-22), 1000 20th St. Bellingham WA 98225-6705 USA, pages 910711, XP055272405, ISSN: 0277-786X, ISBN: 978-1-62841-971-9, DOI: 10.1117/12.2052542 *
MEYERS; MILLER, COMPUTER APPLIC. BIOL. SCI., vol. 4, 1988, pages 11 - 17
WOOTEN; FEDERHEN, COMPUT. CHEM., vol. 17, 1993, pages 149 - 63

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214447A1 (en) * 2016-06-08 2017-12-14 Children's Medical Center Corporation Engineered botulinum neurotoxins
US11104891B2 (en) 2016-06-08 2021-08-31 Children's Medical Center Corporation Engineered botulinum neurotoxins

Also Published As

Publication number Publication date
US20160331800A1 (en) 2016-11-17
CN107624115A (en) 2018-01-23
EP3270951B1 (en) 2020-09-09
CN107624115B (en) 2021-10-26
US20210369807A1 (en) 2021-12-02
US11723944B2 (en) 2023-08-15
US9913875B2 (en) 2018-03-13
US11007245B2 (en) 2021-05-18
US20170218021A1 (en) 2017-08-03
EP3270951A1 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
US11723944B2 (en) Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
US11365219B2 (en) Cyclic peptides as protein targeting agents
US20230019342A1 (en) Phosphorylated akt-specific capture agents, compositions, and methods of using and making
US10975123B2 (en) Mutant Akt-specific capture agents, compositions, and methods of using and making
US11365220B2 (en) Methods of making anti-GP41 antibody-specific capture agents
JP6134725B2 (en) BACE1 peptide inhibitors
HRP20050584A2 (en) Peptides which target tumor and endothelial cells, compositions and uses thereof
CN108290927B (en) IL-17F-specific capture agents, compositions, and methods of use and manufacture
WO2018064597A1 (en) Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
US11719705B2 (en) IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making
WO2020097531A1 (en) Theranostic capture agents, compositions, and methods of using and making
US11919972B2 (en) Peptide libraries with non-canonical amino acids
CN117120458A (en) Peptide ligands targeting carbonic anhydrase IX, peptide structures comprising the same, and uses thereof
WO2020236969A1 (en) Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (ido1)
Leoni et al. structural and biochemical insights of CypA and AIF interaction

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16713229

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2016713229

Country of ref document: EP